

University of Kentucky UKnowledge

Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

10-21-2008

High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same

Chang-Guo Zhan University of Kentucky, chang-guo.zhan@uky.edu

Hoon Cho University of Kentucky

Hsin-Hsiung Tai University of Kentucky, htai1@uky.edu

Click here to let us know how access to this document benefits you.

Follow this and additional works at: https://uknowledge.uky.edu/ps patents



Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation

Zhan, Chang-Guo; Cho, Hoon; and Tai, Hsin-Hsiung, "High-Activity Mutants of Butyrylcholinesterase for Cocaine Hydrolysis and Method of Generating the Same" (2008). Pharmaceutical Sciences Faculty Patents. 44. https://uknowledge.uky.edu/ps_patents/44

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.



US007438904B1

US 7,438,904 B1

Oct. 21, 2008

(12) United States Patent Zhan et al.

(54) HIGH-ACTIVITY MUTANTS OF

(54) HIGH-ACTIVITY MUTANTS OF BUTYRYLCHOLINESTERASE FOR COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME

(75) Inventors: Chang-Guo Zhan, Lexington, KY (US);

Hoon Cho, Lexington, KY (US); Hsin-Hsiung Tai, Lexington, KY (US)

(73) Assignee: University of Kentucky Research

Foundation, Lexington, KY (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 396 days.

(21) Appl. No.: 11/243,111

(22) Filed: Oct. 4, 2005

(51) **Int. Cl.**

A61K 38/46 (2006.01) **C12N 9/16** (2006.01)

(52) **U.S. Cl.** **424/94.6**; 435/196; 435/197

435/197; 424/94.6

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

7,049,121	B2 *	5/2006	Watkins et al 435/196
2003/0153062	A1	8/2003	Watkins et al.
2004/0120939	Al	6/2004	Watkins et al.
2004/0121970	A1	6/2004	Watkins et al.

OTHER PUBLICATIONS

Zhan, et al., Fundamental reaction mechanism for cocaine metabolism in human butyrylcholinesterase, J. Am., Chem. Soc. 2003, 125, 2462-2474.

Hamza, et al., Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants, J. Phys. Chem. B 2005, 109, 4776-4782.

Zhan, et al., Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine, D. Biophysical Journal 2005, 89, 3863-3872.

Gao, et al., Modeling effects of oxyanion hole on the ester hydrolyses catalyzed by human cholinesterases, Phys. Chem. B 2005 109,

Pan, et al., Computational redesign of human butyrylcholinesterase for anti-cocaine medication, C.-G. Proc. Natl. Acad. Sci. USA 2005, 102, 16656-16661.

Gao, et al., Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase, Proteins 2006, 62, 99-110.

Gao, et al., Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation, Angew. Chem. Int. Ed. 2006, 45, 653-657.

Xie, Weihua, et al., An Improved Cocain Hydrolase: The A328Y Mutant of Human Butyrylcholinesterase is 4-Fold More Efficient; Molecular Pharm; 1995; 55; pp. 83-91.

* cited by examiner

23070-23076.

(10) Patent No.:

(45) **Date of Patent:**

Primary Examiner—Tekchand Saidha (74) Attorney, Agent, or Firm—Stites & Harbison PLLC; Stephen Weyer; James Daly, IV

(57) ABSTRACT

A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/ Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/ A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (-)-cocaine compared with wild-type BChE.

4 Claims, 6 Drawing Sheets







FIGURE 1




(A) BChE-(-)-cocaine non-prereactive complex



(B) BChE-(-)-cocaine prereactive complex



(C) BChE-(+)-cocaine non-prereactive complex



(D) BChE-(+)-cocaine prereactive complex

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

HIGH-ACTIVITY MUTANTS OF BUTYRYLCHOLINESTERASE FOR COCAINE HYDROLYSIS AND METHOD OF GENERATING THE SAME

FIELD OF THE INVENTION

The present invention relates to butyrylcholinesterase variant polypeptides, and in particular, butyrylcholinesterase 10 mutants having amino acid substitutions.

BACKGROUND OF THE INVENTION

Cocaine abuse is a major medical and public health problem that continues to defy treatment. The disastrous medical and social consequences of cocaine addiction, such as violent crime, loss in individual productivity, illness and death, have made the development of an effective pharmacological treatment a high priority. However, cocaine mediates its reinforcing and toxic effects by blocking neurotransmitter reuptake and the classical pharmacodynamic approach has failed to yield small-molecule receptor antagonists due to the difficulties inherent in blocking a blocker. An alternative to receptor-based approaches is to interfere with the delivery of cocaine to its receptors and accelerate its metabolism in the body.

The dominant pathway for cocaine metabolism in primates is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the ³⁰ benzoyl ester group (Scheme 1).

-continued

H₃C

OCH₃

+ H₂O

BChE

O Scheme 1. Schematic representation of BChE-catalyzed hydrolysis at the benzoyl ester group.

Only 5% of the cocaine is deactivated through oxidation by the liver microsomal cytochrome P450 system. Cocaine hydrolysis at benzoyl ester group yields ecgonine methyl ester, whereas the oxidation produces norcocaine. The metabolite ecgonine methyl ester is a biologically inactive metabolite, whereas the metabolite norcocaine is hepatotoxic and a local anesthetic. BChE is synthesized in the liver and widely distributed in the body, including plasma, brain, and lung. Extensive experimental studies in animals and humans demonstrate that enhancement of BChE activity by administration of exogenous enzyme substantially decreases cocaine half-life.

Enhancement of cocaine metabolism by administration of BChE has been recognized to be a promising pharmacokinetic approach for treatment of cocaine abuse and dependence. However, the catalytic activity of this plasma enzyme is three orders-of-magnitude lower against the naturally occurring (–)-cocaine than that against the biologically inactive (+)-cocaine enantiomer. (+)-cocaine can be cleared from plasma in seconds and prior to partitioning into the central nervous system (CNS), whereas (–)-cocaine has a plasma half-life of approximately 45-90 minutes, long enough for manifestation of the CNS effects which peak in minutes. Hence, BChE mutants with high activity against (–)-cocaine are highly desired for use in humans. Although some BChE mutants with increased catalytic activity over wild-type

BChE have previously been generated, there exists a need for mutant BChE with even higher catalytic activity. Thus, prior mutants provide limited enhancement in catalytic activity over wild-type BChE.

Previous studies such as (a) Masson, P.; Legrand, P.; Bar- 5 tels, C. F.; Froment, M-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, 10 J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J. 15 Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner, G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261; (g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.; Brimijoin, S.; Pang, Y.-P. J. Biol. Chem. 2001, 276, 9330, (h) Sun, H.; Shen, M. L.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. 20 J. Pharmacol. Exp. Ther. 2002, 302, 710, (i) Sun, H.; Pang, Y. P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62, 220 (hereinafter "Sun et al"); and (j) Zhan, C.-G.; Zheng, F.; Landry, D. W. J. Am. Chem. Soc. 2003, 125, 2462 (hereinafter "Zhan et al"), herein all incorporated by reference, suggested 25 that, for both (-)-cocaine and (+)-cocaine, the BChE-substrate binding involves two different types of complexes: non-prereactive and prereactive BChE-substrate complexes. Whereas the non-prereactive BChE-cocaine complexes were first reported by Sun et al, Zhan et al were the first reporting 30 the prereactive BChE-cocaine complexes and reaction coordinate calculations, disclosed in Zhan et al. It was demonstrated that (-)/(+)-cocaine first slides down the substratebinding gorge to bind to W82 and stands vertically in the gorge between D70 and W82 (non-prereactive complex) and 35 then rotates to a position in the catalytic site within a favorable distance for nucleophilic attack and hydrolysis by S198 (prereactive complex). In the prereactive complex, cocaine lies horizontally at the bottom of the gorge. The main structural difference between the BChE-(-)-cocaine complexes and the 40 corresponding BChE-(+)-cocaine complexes exists in the relative position of the cocaine methyl ester group. Reaction coordinate calculations revealed that the rate-determining step of BChE-catalyzed hydrolysis of (+)-cocaine is the chemical reaction process, whereas for (-)-cocaine the 45 change from the non-prereactive complex to the prereactive complex is rate determining. A further analysis of the structural changes from the non-prereactive complex to the prereactive complex reveals specific amino acid residues hindering the structural changes, providing initial clues for the rational 50 design of BChE mutants with improved catalytic activity for (-)-cocaine.

Previous molecular dynamics (MD) simulations of prereactive BChE-cocaine binding were limited to wild-type BChE. Even for the non-prereactive BChE-cocaine complex, 55 only one mutant (A328W/Y332A) BChE binding with (–)-cocaine was simulated and its catalytic activity for (–)-cocaine was reported by Sun et al. No MD simulation was performed on any prereactive enzyme-substrate complex for (–)- or (+)-cocaine binding with a mutant BChE. In addition, 60 all previous computational studies of Sun et al and Zhan et al of BChE interacting with cocaine were performed based on a homology model of BChE when three-dimensional (3D) X-ray crystal structure was not available for BChE, as taught by Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, 65 J. C.; Nachon, F. J. Biol. Chem. 2003, 278, 41141 (hereinafter "Nicolet et al"), recently reported 3D X-ray crystal structures

4

of BChE. As expected, the structure of BChE is similar to a previously published theoretical model of this enzyme and to the structure of acetylcholinesterase.

The main difference between the experimentally determined BChE structure and its model was found at the acyl binding pocket (acyl loop) that is significantly bigger than expected. It is unclear whether the structural difference at the acyl binding pocket significantly affect BChE binding with (–)-cocaine and (+)-cocaine. Although previous MD simulations of cocaine binding with wild-type BChE and the reaction coordinate calculations point to some amino acid residues that might need to be mutated for the purpose of improving the catalytic activity for (–)-cocaine hydrolysis, it remained unknown which exact amino acid mutations will result in a BChE with a higher catalytic activity for (–)-cocaine.

Computational studies of wild-type BChE and cocaine from Sun, et al, based on a "homology model," suggest that the rate-determining step for BChE-catalyzed hydrolysis of cocaine is the rotation of the cocaine in the active site of BChE. By decreasing the hindrance of the rotation, the rate of the hydrolysis may be enhanced. Sun, et al describes creating an A328W/Y332A BChE mutant by: (1) replacing Tyr332 with Ala, "to reduce the steric hindrance and the p-p interaction that impede rotation," and (2) replacing Ala328 with Trp "to provide a cation-p interaction to restore substrate affinity lost in disabling the p-p interaction."

Sun et al studied the A328W/Y332A BChE mutant using enzyme assays and kinetics. In vitro studies were conducted using human plasma and in vivo studies were conducted using male Sprague-Dawley rats. The mutant was found to have enhanced catalytic properties. The mutant was further studied using molecular modeling. The three dimensional (3D) structure of A328W/Y332A was generated from the computationally generated 3D model of wild-type BChE and changing the relevant residues using commercially available software. Cocaine was docked to the catalytic gorge of the mutant BChE using other commercially available software. The cocaine-enzyme complex was refined by molecular dynamic simulation. The data generated by the molecular modeling studies were consistent with enzyme assays and kinetic data.

It should be noted that all prior computational techniques (molecular docking and molecular dynamics simulation) used by other researchers are based on an empirical force field which cannot be used to perform any necessary reaction coordinate calculation for the detailed understanding of the complicated catalytic reaction process. As it is well-known, it is particularly challenging to model and simulate the detailed reaction pathway and predict the kinetics of such an enzymatic reaction.

U.S. Patent Application Publication Nos. 2004/0121970; 2004/0120939; and 2003/0153062, describe 20+BChE mutants, or "variants," from human and other animals, each having from one to six amino acid alterations and increased cocaine hydrolysis activity. For example, mutants include F227A/A328W; F227A/S287G/A328W; A119S/S287G/A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/287G/A328W and A119S/F227A/S287G/A328W/Y332M. The mutants have varying increases in catalytic activity, up to 100-fold increase relative to wild-type BChE.

There exists a need in the art for determining which proposed mutant BChEs should have ever increasing catalytic activity and for generating those mutants which should have enhanced catalytic activity.

SUMMARY OF THE INVENTION

The present invention includes five novel human BChE mutants that have unexpected increased catalytic efficiency for cocaine hydrolysis. The mutants have various unique 5 amino acid residue substitutions which provide the surprising enhanced catalytic activity. These mutants are (1) A199S/ A328W/Y332G mutant (SEQ ID NO: 2), which has a approximately 65-fold improved catalytic efficiency against (-)-cocaine; (2) A199S/F227A/A328W/Y332G mutant 10 (SEQ ID NO: 8), which has an approximately 148-fold improved catalytic efficiency against (-)-cocaine; (3) A199S/ S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has an approximately 456-fold improved catalytic efficiency against (-)-cocaine; (4) A199S/F227A/S287G/A328W/ 15 Y332G mutant (SEQ ID NO: 20), which has an approximately 1,003-fold improved catalytic efficiency against (-)cocaine; and (5) A199S/F227A/S287G/A328W/E441D mutant (SEQ ID NO: 26), which has an approximately 445fold improved catalytic efficiency against (-)-cocaine.

In addition, the aforementioned mutant amino acid sequences can be truncated without substantially affecting the catalytic activity so that amino acid residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22 25 and 28 are the amino acid sequences for residue 68-142 corresponding to mutants 1-5, respectively. In addition, with regard to mutants 1-4, it was found that amino acid residues before 117 and after 438 could be removed without substantially changing the activity of the mutant enzymes, resulting in truncated amino acid sequences having SEQ ID NOS: 6, 12, 18 and 24, respectively. Finally with regard to mutant 5, amino acid residues before 117 and after 441 could be removed without substantially changing its activity resulting in SEQ ID NO: 30.

These aforementioned truncated sequences all of with similar catalytic activity is based on protein structures.

Further, the present invention is directed to a novel and unique pharmaceutical composition which comprises a butyrylcholinesterase variant, namely mutants 1-5, along 40 with a suitable pharmaceutical carrier. The pharmaceutical composition can be administered to an individual in an effective amount to lower the patient's cocaine blood concentration and in particular (–)-cocaine blood concentration.

In addition, the present invention is directed to a novel and 45 unique method for developing mutants which have enhanced catalytic efficiency. The generation method includes both a computational portion and an experimental portion. With regard to the computational portion, a variety of state of the art computational techniques including molecular modeling, 50 molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations, provide a virtual screening of possible BChE mutants. This virtual screening predicts which mutation will lead to a more stable transition state for a rate-determining step compared to 55 the corresponding separated reactants, i.e., free cocaine and free enzyme. The more stable the transition state, the lower the energy barrier, and the higher the catalytic efficiency. Following the computational portion, an experimental test is then conducted on the possible mutants of the computation 60 portion. The experimental test includes site-directed mutagenesis, protein expression, and enzyme activity assay. The experimental tests are conducted on mutants which are predicted to have a high catalytic efficiency against (-)-cocaine than the wild-type BChE and/or other known BChE 65 mutants against (-)-cocaine. Thus, the present method identifies or predicts mutants having high catalytic activity for

6

cocaine hydrolysis by performing molecular modeling and MD simulations on the transition state structures of possible mutants of BChE. This method is an improvement over traditional random-search approaches, which, given the complex catalytic mechanism of cocaine hydrolysis, makes it difficult to improve the catalytic activity of BChE for cocaine hydrolysis.

The present invention in one form, concerns a butyrylcholinesterase variant peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

The present invention in another form thereof concerns a nucleic acid molecule comprising a nucleic acid sequence which encodes a butyrylcholinesterase variant peptide, the nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, and 29

The present invention in another form thereof concerns a pharmaceutical composition comprising a butyrylcholinest-20 erase variant polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable pharmaceutical carrier.

The present invention in another form thereof concerns a method for treating a cocaine-induced condition comprising administering to an individual an effective amount of butyrylcholinesterase variant peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood occaine concentration.

The present invention is another form thereof concerns a method for treating a cocaine induced condition comprising administering to an individual an effective amount of a pharmaceutical composition comprising a butyrylcholinesterase variant having an amino acid sequence selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier of claim 3 to an individual in an effective amount to lower blood cocaine concentration.

The present invention in yet another form thereof concerns a method for generating butyrylcholinesterase mutants. The method includes generating an initial structure of the transition state structure for the rate-determining step of the cocaine hydrolysis catalyzed by a possible butyrylcholinesterase mutant. A sufficiently long time molecular dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajectory. The molecular dynamics trajectory is analyzed and the hydrogen bonding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzyl ester and the oxyanion hole of the possible butyrylcholinesterase mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)cocaine benzyl ester and the possible butyrylcholinesterase mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzyl ester and the wild-type butyrylcholinesterase, optionally, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. Finally, the butyrylcholinesterase mutant is generated.

In various alternative embodiments, the generating an initial structure of the transition state structure is based on reaction coordinate calculations for the wild-type butyrylcholinesterase. The generating butyrylcholinesterase mutant includes performing site-directed mutagenesis on a nucleic

acid sequence which includes wild-type butyrylcholinesterase to generate the mutant butyrylcholinesterase nucleic acid sequence. Using the mutant butyrylcholinesterase nucleic acid sequence, the protein encoded by the mutant nucleic acid sequences is expressed to produce mutant 5 butyrylcholinesterase and catalytic activity assay is performed on the mutant butyrylcholinesterase.

The hybrid quantum mechanical/molecular mechanical geometry optimization may include calculating the hydrogen binding energies and evaluating the energy barriers only if the overall hydrogen binding energy between the carboxyl oxygen of the (–)-cocaine benzyl ester and the possible butyryl-cholinesterase mutant, in the transition state, is stronger than known butyrylcholinesterase mutants against (–)-cocaine.

In yet another alternative further embodiment, the method 15 for generating butyrylcholinesterase mutants further includes determining the rate-limiting step in the hydrolysis of (–)-cocaine by the possible butyrylcholinesterase mutant by conducting molecular dynamics simulations and quantum mechanical/molecular mechanical calculations relating to the 20 transition states for other reaction steps between (–)-cocaine by the possible butyrylcholinesterase mutant and calculating respective energy barriers, thereby establishing which of the reaction steps is the rate-determining one.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 are plots of distances in the MD simulation (–)-cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-mean-square deviation (RMSD) 30 in the enzyme-substrate complexes where FIG. 1A represents the non-prereactive enzyme-substrate complexes; and FIG. 1B represents the prereactive enzyme-substrate complexes in accordance with the present invention.

FIG. 2 shows the binding of structures of the simulated 35 non-prereactive and prereactive complexes of wild-type BChE binding with two entomers of cocaine in which FIG. 2A depicts BChE (-)-cocaine non-prereactive complex; FIG. 2B depicts BChE (-)-cocaine prereactive complex, FIG. 2C depictes BChE (+)-cocaine non-prereactive complex; and 40 FIG. 2D depicts BChE (+)-cocaine prereactive complex.

FIG. 3A shows the (-)-cocaine rotation in the BChE active site for the non-prereactive complex to the prereactive complex hindered by some residues at positions Y332, A328, and F329 residues in the non-prereactive complexes which are significantly different from the corresponding positions in the prereactive complex; and FIG. 3B shows the (+)-cocaine rotation in the BChE active site where none of the aforemen-

8

tioned residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex in accordance with the present invention.

FIG. 4A depicts the (–)-cocaine rotation in the active site of A328W/Y332A; FIG. 4B depicts the (–)-cocaine rotation in the active site of A328W/Y332G BChE from the non-preactive complex to the prereactive complex; and FIG. 4C depicts the (–)-cocaine rotation in the active site of wild-type BChE.

FIG. **5**A is a plot of the key internuclear distances (in Å) versus the time in the simulated TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A; and FIG. **5**B for A199S/A328W/Y332G BChE.

FIG. **6** is a plot of key internuclear distances (in A) versus the time in the simulated TS1 structure for (–)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention has two major improvements over the prior art. The first is the presently discovered BChE mutants, mutant 1, A199S/A328W/Y332G; mutant 2, A199S/F227A/A328W/Y332G; mutant 3, A199S/S287G/A328W/Y332G; mutant 4, A199S/F227A/S287G/A328W/Y332G; and mutant 5, A199S/F227A/S287G/A328W/E441 D each have a significantly higher catalytic efficiency. The second improvement is concerning the mutant designing or discovering process.

The BChE mutants 1-5 have full length amino acid sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively, which are encoded by nucleic acid sequences having SEQ ID NOS: 1, 7, 13, 19, and 25, respectively. Table 1 summarizes the catalytic efficiency against (–)-cocaine for the five mutants.

In addition to the full length BChE mutants, the respective amino acid sequence can be truncated without substantially affecting the respective catalytic activity. With all mutants, residues 1-67 and 443-574 can be removed without substantially affecting the catalytic activity of the respective mutant BChE. Further, with regard to mutant 1-4, amino acids 1-116 and 439-574 can be omitted without substantially affecting its respective catalytic activity. With regard to mutant 5, amino acid residues 1-116 and 442-574 can be omitted without substantially affecting its catalytic activity. Table 1 also provides a summary of amino acid SEQ ID NOS and corresponding nucleic acid SEQ ID NOS for the aforementioned truncated mutant BChE sequences.

TABLE 1

Mutant Number	Amino Acid Substituting	Nucleic Acid SEQ ID NO.	Amino Acid SEQ ID NO.	Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Residues 68-442	SEQ ID NO. for Amino Acid Residues 68-442	SEQ ID NO Corresponding To Amino Acid Residues 117-438/441*	SEQ ID NO. for Amino Acid Residues 117-438/441*	Catalytic Efficiency Against (–)-cocaine
1	A199S/A328W/	1	2	3	4	5	6	65-fold
2	Y332G A199S/F227A/	7	8	9	10	11	12	148-fold
2	A328W/Y332G	,	0	9	10	11	12	146-1010
3	A199S/S287G/	13	14	15	16	17	18	456-fold
	A328W/Y332G							
4	A199S/F227A/	19	20	21	22	22	24	1,003-fold
	S287G/A328W/ Y332G							

TABLE 1-continued

Mutant Number	Amino Acid Substituting	Nucleic Acid SEQ ID NO.		Partially Truncated Nucleic Acid Sequence Corresponding To Amino Acid Residues 68-442	SEQ ID NO. for Amino Acid Residues 68-442	SEQ ID NO Corresponding To Amino Acid Residues 117-438/441*	SEQ ID NO. for Amino Acid Residues 117-438/441*	Catalytic Efficiency Against (–)-cocaine
5	A199S/F227A/ S287G/A328W/ E441D	25	26	27	28	29	30	445-fold

(*Amino acid residues 117-438 for mutants 1-4 and residues 117-441 for mutant 5.)

8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be formulated in a pharmaceutical composition along with a suitable pharmaceutical carrier known to one skilled in the

9

The present BChE variant polypeptides can be used in 20 treating a cocaine-induced condition by administering to an individual, an effective amount of one of the BChE variant polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood cocaine concentration. The BChE variant polypeptide may be administered in 25 the form of a pharmaceutical composition in which the BChE variant is included with a suitable pharmaceutical carrier. Treatment of a cocaine induced condition using one of the aforementioned BChE variant polypeptides can be done in accordance with Zhan et al., page 2463.

The preferred dose for administration of a butyrylcholinesterase or peptide composition in accordance with the present invention is that amount which will be effective in lowering (-)-cocaine concentration in a patient's bloodstream, and one would readily recognize that this amount will 35 vary greatly depending on the nature of cocaine consumed, e.g., injected or inhaled, and the condition of a patient. An "effective amount" of butyrylcholinesterase mutant or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the 40 agent, such that the desired prophylactic or therapeutic effect is produced. Thus, the exact amount of the enzyme or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the 45 particular carrier or adjuvant being used and its mode of administration, and the like. Similarly, the dosing regimen should also be adjusted to suit the individual to whom the composition is administered and will once again vary with age, weight, metabolism, etc. of the individual. Accordingly, 50 the "effective amount" of any particular butyrylcholinesterase composition will vary based on the particular circumstances, and an appropriate effective amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation.

A unique method was used to determine potential BChE mutants with projected increased catalytic activity for the hydrolysis of cocaine. The method provides a unique approach which first models the potential BChE mutant interaction with cocaine followed by generating the BChE mutant 60 if the predicted model indicates that the BChE variant should have enhanced catalytic activity. The method includes generating an initial structure of the transition state structure for the rate-determining step for the cocaine hydrolysis catalyzed by a possible BChE mutant. A sufficiently long time molecular 65 dynamics simulation is performed on the transition state structure in water to have a stable molecular dynamics trajec-

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6, 15 tory. The molecular dynamics trajectory is analyzed and the hydrogen binding energies are estimated between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the oxyanion hole of the possible BChE mutant. If the overall hydrogen binding energy between the carboxyl oxygen of the (-)cocaine benzoyl ester and the possible BChE mutant, in the transition state, is stronger than the overall hydrogen binding energy between the carboxyl oxygen of the (-)-cocaine benzoyl ester and the wild-type BChE, hybrid quantum mechanical/molecular mechanical (QM/MM) geometry optimization is performed to refine the molecular dynamics-simulated structure, the hydrogen binding energies are calculated and the energy barrier is evaluated. The QM/MM calculations make the computational predictions more reliable. Finally, the BChE mutant is generated.

> With regard to the molecular dynamics (MD) simulations and quantum mechanical/molecular mechanical (QM/MM) calculations, the first chemical reaction step of (-)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants and, when needed, other reaction steps are modeled and calculated using molecular dynamics simulations and QM/MM calculations. Following this modeling, mutant BChE's are created using site-directed mutagenesis followed by protein expression. The aforementioned five mutants were identified by computational analysis and generated by sitedirected mutagenesis which have significantly enhanced (-)cocaine hydrolysis catalytic efficiency compared with wildtype BChE.

> In the present method computational analysis in the form of molecular modeling of a potential BChE mutant and MD simulations and QM/MM calculations provide virtual screening of possible BChE mutants which have predicted enhanced catalytic activity for (-)-cocaine. For example, the MD simulations and QM/MM calculations predict which mutation will lead to a more stable transition state for the rate determining step compared to the corresponding separated reagents, i.e., free cocaine and free possible mutant BChE, where the more stable transition state leads to a lower energy barrier and higher predicted catalytic efficiency. Only after the computational analysis predicts enhanced catalytic efficiency, is sitedirected mutagenesis conducted on wild-type BChE nucleic acid sequence to generate a mutant nucleic acid sequence which is then used to express a mutant BChE protein. The mutant BChE protein is then used in catalytic assays to determine the catalytic efficiency against (-)-cocaine.

> The use of predictive, computational modeling of the present method for identifying mutant BChE candidates and the resulting mutant BChE are novel and unexpected over prior conventional methods which will now be readily apparent to one of ordinary skill in the art.

> Using the present method, most discovered new mutants include a specific mutation (Y332G) on residue #332. No prior BChE mutant having the Y332G mutation had ever been

reported previously; only mutations Y332A and Y332M on residue #332 had been tested previously by other researchers. Prior to the present invention, there was no reason to expect that a mutant including Y332G mutation should be better than the corresponding mutant including Y332A mutation or Y332M. Thus, the present mutants with a Y332G mutation which have enhanced catalytic activity represent a surprising and unexpected result over prior BChE mutants.

A Y332G mutant (single mutation) was first tested and found that the Y332G mutant had a slightly low (or approximately equal) catalytic efficiency than the wild-type. So, only an appropriate combination of different mutations on different residues could make the enzyme more active. As seen below, the prior art did not reveal that any of the particular combinations tested was expected to have an improved catalytic efficiency. The present method is based on the present unique, extensive computational modeling and simulations of the detailed catalytic mechanism for both the wild-type BChE and the mutants

The primary improvement of the present method over the prior art is that high-performance computational modeling and simulations of the detailed catalytic mechanism are performed, which includes modeling how cocaine binds with BChE and the subsequent structural transformation and chemical reaction process. The prior art only considered the cocaine binding with the enzyme (BChE) and was unable to examine the detailed catalytic reaction process after the BChE-cocaine binding. When molecular modeling was limited to studying the BChE-cocaine binding, one could only design a mutation to improve the BChE-cocaine binding without knowing whether the mutation will also speedup the subsequent chemical reaction process or not.

To overcome the obstacles of prior challenges to using computational techniques such as molecular docking and 35 molecular dynamics simulation previously used by others which were based on an empirical force field which cannot be used to perform necessary reaction coordinate calculations for the catalytic reaction process, a variety of state-of-the-art computational techniques of homology modeling, molecular 40 docking, molecular dynamics, quantum mechanics (QM), and hybrid quantum mechanics/molecular mechanics (QM/ MM) were used for the rational design of the BChE mutants. The combined use of these computational techniques, including QM and QM/MM, led to the study of the detailed reaction 45 coordinate of the BChE-catalyzed hydrolysis of cocaine which, for the first time, provided the detailed structures of all transition states and intermediates existing in the reaction process and the corresponding energetics. These extensive computational modeling and simulation studies provided for 50 the rational design of possible BChE mutants that not only can improve the BChE-cocaine binding, but also can speedup the subsequent chemical reaction process. As a result, one can now quickly discover the BChE mutants with the significantly improved catalytic efficiency.

In addition, to the differences mentioned above, the present molecular modeling of the BChE-cocaine binding also differs from the prior modeling. The molecular modeling in the prior art considered only one binding mode for each BChE-cocaine system, without modeling the possible cocaine rotation in the 60 BChE active site after the binding. The present method considers two different binding modes for each BChE-cocaine system and the structural transformation between them: non-prereactive and prereactive BChE-cocaine complexes. The present modeling provides more detailed information about 65 the BChE-cocaine binding and the subsequent structural transformation.

12

The present method includes molecular dynamics simulations performed on the cocaine binding with both the wild-type BChE and the mutants whereas prior molecular dynamics simulations were only performed on the cocaine binding with the wild-type BChE. As is shown below in the following experiments, the computational prediction could be completely wrong without directly modeling and simulating cocaine binding with the proposed mutants.

The present invention will now be discussed with regard to the following non-limiting examples in the form of experiments which are provided to enhance understanding of the present invention but in no way limit its scope or applicability.

Experiment 1

Computational Study of Cocaine Binding with Wild-Type and Mutant BChE's for A328W/Y332G, A328W/Y332A, and A328W/Y332A/Y419S

A detailed computational study of cocaine binding with wild-type and mutant BChE's starting from the available X-ray crystal structure of wild-type BChE was performed. The simulated mutants include A328W/Y332G, A328W/Y332A, and A328W/Y332A/Y419S, as simple geometric consideration of the binding site suggests that these mutations could be important for changing the (–)-cocaine rotation from the non-prereactive complex to the prereactive complex. Wet experimental tests were conducted on the catalytic activity of these mutants for (–)-cocaine in order to verify the computational predictions. All of the obtained results clearly demonstrate that molecular modeling and MD simulations of cocaine binding with BChE mutants provide a reliable computational approach to the rational design of high-activity mutants of BChE for the (–)-cocaine hydrolysis.

3D model of BChE. The initial coordinates of human BChE used in the computational studies came from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1 POP). The missing residues (D2, D3, E255, D378, D379, N455, L530, E531, and M532) in the X-ray crystal structure were built using the automated homology modeling tool Modeler disclosed by Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1990, 212 403, and Sali, A.; Blundell, T. L. *J. Mol. Biol.* 1993, 234, 779, herein incorporated by reference, and Insightll software (Accelrys, Inc.) with the default parameters.

Molecular docking. Molecular docking was performed for each non-prereactive protein-ligand binding complex. The binding site was defined as a sphere with an approximately 15 Å radius around the active site residue S198. The amino acid residues included in the binding site model are not contiguous in the protein. Cocaine, considered as a ligand, was initially positioned at 17 Å in front of S198 of the binding site. Each BChE-cocaine binding complex was energy-minimized by using the steepest descent algorithm first until the maximum 55 energy derivative is smaller than 4 kcal/mol/Å and then the conjugated gradient algorithm until the maximum energy derivative is smaller than 0.001 kcal/mol/Å. The energy minimization was followed by a 300 ps molecular dynamics (MD) simulation at T=298 K with a time step of 1 fs. During the energy minimization and MD simulation, only cocaine and the residues of BChE included in the binding site were allowed to move, while the remaining part of the protein was fixed. The energy-minimization and MD simulation for these processes were performed by using the Amber force field implemented in the Discover_3/InsightII calculation engine, disclosed by Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.;

Fox, T.; Caldwell, J. W.; Kollman, P. A. *J. Am. Chem. Soc.* 1995, 117, 5179. The non-bonded cut-off method and the dielectric constant were set up to group based (12 Å cut-off distance) and distance dependent, respectively (ϵ =4r) in accordance with Harvey, S. C. *Proteins* 1989, 5, 78-92, herein ⁵ incorporated by reference.

Molecular dynamic simulation in water. The initial coordinates used in the MD simulation of the non-prereactive complexes were determined by using the molecular docking procedure described above, whereas the initial coordinates used in the MD simulation of the prereactive complexes were obtained from superimposing backbone of the X-ray crystal structure to that of the previously disclosed simulated prereactive complex of Zhan et al between cocaine and a homology model of wild-type BChE. Each BChE-cocaine binding complex was neutralized by adding two chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å. The general procedure for carrying out the MD simulations in water is similar to that used in our previously reported other computational studies such as those in Zhan et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Riftenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rit-25 tenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, R. L. J. Comput. Chem. 2003, 24, 368, herein all incorporated by reference. These simulations were performed by using the Sander module of Amber7 program as taught by Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; 35 Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. (2002), AMBER 7, University of California, San Francisco, herein incorporated by reference. The solvated system was optimized prior to the MD simulation. First, the proteinligand was frozen and the solvent molecules with counterions were allowed to move during a 5000-step minimization with the conjugate gradient algorithm and a 5 ps MD run at T=300 K. After full relaxation and the entire solvated system was energy-minimized, the system was slowly heated from T=10 45 K to T=300 K in 30 ps before the production MD simulation for 500 ps. The full minimization and equilibration procedure was repeated for each mutant. The MD simulations were performed with a periodic boundary condition in the NPT ensemble at T=300 K with Berendsen temperature coupling and constant pressure (P=1 atm) with isotropic moleculebased scaling disclosed in Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. J. Comp. Phys. 1984, 81, 3684, herein incorporated by reference. The 55 SHAKE algorithm of Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. C. J. Comp. Phys. 1977, 23, 327 (herein incorporated by reference) was applied to fix all covalent bonds containing a hydrogen atom, a time step of 2 fs was used, and the non-bond pair list was updated every 10 steps. The pressure was adjusted by isotropic position scaling. The particle mesh Ewald (PME) method of Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen; L. G. J. Chem. Phys. 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A residue-based cutoff of 10 Å was applied to the noncovalent interactions.

14

During the 500 ps production MD simulation, the coordinates of the simulated complex were saved every 1 ps.

Molecular docking and MD simulation procedures described above were performed to study cocaine binding with wild-type BChE and three mutants, i.e., A328W/Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For each protein system (wild-type or mutant BChE), the protein binding with cocaine was considered in both the non-prereactive and prereactive enzyme-substrate complexes.

Most of the MD simulations in water were performed on a supercomputer, Superdome (shared-memory, with 4 nodes and 256 processors), at the Center for Computational Sciences, University of Kentucky. The other computations were carried out on SGI Fuel workstations and a 34-processors IBM x335 Linux cluster.

Experimental procedure. Site-directed mutagenesis of human BChE cDNA was performed by the QuikChange method of Braman, J.: Papworth, C.: Greener, A. Methods Mol. Biol. 1996, 57, 5731, herein incorporated by reference. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, all herein incorporated by reference, kindly provided by Dr. Lockridge at University of Nebraska Medical Center. Using plasmid DNA as template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into Escherichia coli, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequencing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO₂ incubator for 24 hours and cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure cocaine and benzoic acid, the product of cocaine hydrolysis by BChE, we used sensitive radiometric assays based on toluene extraction of [3H] cocaine labeled on its benzene ring were used in accordance with Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, herein incorporated by reference. In brief, to initiate reactions, 100 nCi of [³H]cocaine was mixed with 100 µl of culture medium. Reactions proceeded at 37° C. for varying times. Reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual cocaine. [3H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the measured timedependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency (k_{car}/K_M) was determined.

Depicted in FIG. 1 are plots of some important distances in the MD-simulated (–)-cocaine binding with A328W/Y332G BChE versus the simulation time, along with root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simulated structure from those in the X-ray crystal structure. MD trajectories for other complexes were similar to these two in FIG. 1, although the simulated average distances are different. Summarized in Table 2 are the average values of some important geometric parameters in the simulated complexes.

TABLE 2


	Average	Average values of the geometric parameters ^c										
BChE-cocaine binding ^a	${\rm <\!D1\!>_{non}}$	<d1></d1>	<d2></d2>	<d3></d3>	<d4></d4>	<t></t>	nonpre	re				
wild-type wild-type with (+)-cocaine ^b A328W/Y332A A328W/Y332G A328W/Y332A/Y419S	5.60 7.64 7.11 7.06 5.18	.27 .69 .87 .96 .84	.77 .88 .30 .28 .64	.71 .30 .14 .52 .56	.37 .83 .01 .42 .97	67 61 51 60 64	1.14 1.15 1.58 1.20 2.66	.27 .13 1.65 .35 .62				

^aRefers to (-)-cocaine binding with wild-type human BChE or (-)-cocaine binding with a mutant BChE, unless indicated otherwise. ^bRefers to (+)-cocaine binding with wild-type human BChE.

°<D1>non and <D1> represent the average distances between the S198 O' atom and the carbonyl carbon of the cocaine benzoyl ester in the simulated non-prereactive and prereactive BChE-cocaine complexes, respectively. <D2>, <D3>, <D4> refer to the average values of the simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH hydrogen atoms of G116, G117, and A199 residues, respectively. <T> is the average value of the dihedral angle formed by the S198 O² atom and the plane of the carboxylate group of the cocaine benzoyl ester. See Scheme 2. dThe root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the simulated

structure from those in the X-ray crystal structure of BChE. "nonpre" and "pre" refer to the nonprereactive and prereactive BChE-cocaine complexes, respectively.

(-)- and (+)-cocaine binding with wild-type BChE. FIG. 2 shows the binding structures of the simulated non-prereactive and prereactive complexes of wild-type BChE binding with $\ ^{25}$ the two enantiomers of cocaine. In the non-prereactive complexes with (-)- and (+)-cocaine, the methyl ester group of cocaine is positioned at the top of the H438 backbone, while the cocaine benzoyl ester moiety is quasi-parallel to the C— O^2 side chain of S198 with a dihedral angle T of -8° and 30 140°, respectively.



Scheme 2. Hydrolysis of (-)-cocaine and (+)-cocaine.

Here, T refers to the dihedral angle formed by S198 O? and 55 the plane of carboxylate group of the cocaine benzoyl ester as shown in the structure diagram below.

The simulated internuclear distances between the carbonyl oxygen of cocaine benzoyl ester group and the NH hydrogen of G116, G117, and A199 are comparable for the two enantiomers. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O² are 5.60 Å and 5.18 Å for (-)- and (+)-cocaine, respectively. Comparing the simulated protein backbone structures to the X-ray crystal structure of Nicolet et al, one can see from FIG. 1 that the RMSD values are all smaller than 1.3 Å for the whole protein structures.

The MD simulations of the prereactive complexes reveal that wild-type BChE binding with (-)-cocaine is essentially the same as the binding with (+)-cocaine in the binding site, except for the different positions of methyl ester group of the substrates. The simulated average distances between the carbonyl carbon of the benzoyl ester and S198 O? are 3.27 and 3.69 Å for (-)-cocaine and (+)-cocaine, respectively. Moreover, the (+)-cocaine is stabilized more effectively by the formation of strong hydrogen bonds with the backbone NH of residues G116, G117, and A199 as summarized above in Table 2. The cocaine benzoyl ester moiety is positioned quasiperpendicular to S198 C—O? with a dihedral angle T of ~67° and ~61° for (-)- and (+)-cocaine, respectively.

A comparison was made between the currently simulated structures of the BChE-cocaine binding with those simulated previously by using a homology model of BChE and it was noted that two major differences between the two sets of structures. By using the X-ray crystal structure in accordance with Nicolet et al, the acyl loop is positioned on the top of the cocaine benzoyl ester moiety of the cocaine, whereas the acyl loop is far from the cocaine benzoyl ester moiety in the 45 structure simulated starting from the homology model of Zhan et al. The RMSD of the coordinates of backbone atoms in the previously simulated prereactive BChE-(-)-cocaine complex from those in the X-ray crystal structure of BChE is ~2.0 Å for the entire protein and ~3.0 Å for the acyl loop. The 50 RMSD value became ~2.4 Å for the entire protein and ~3.3 Å for the acyl loop, when the X-ray crystal structure was replaced by the MD-simulated prereactive BChE-(-)-cocaine complex starting from the X-ray crystal structure. Despite these structural differences, the benzoyl ester group of the ligand is still close to the key residues (S197, G116, and G117) in the BChE binding site. Some significant differences are associated with the distances between the S198 O? atom and the carbonyl carbon of the cocaine benzoyl ester in nonprereactive complexes. The average values of this distance in the non-prereactive complexes were ~9.5 and ~8.5 Å for (-)and (+)-cocaine, respectively, when a homology model was used. Using the X-ray crystal structure to conduct the analysis, corresponding average values became ~5.6 and ~5.2 Å, respectively. Therefore, both (-)- and (+)-cocaine became closer to the binding site when the homology model was replaced by the X-ray crystal structure. However, no significant changes of the binding in the prereactive complexes were

observed when the used homology model was replaced by the X-ray crystal structure. The average values of the simulated distance between the S198 O² atom and the carbonyl carbon of the cocaine benzoyl ester in the prereactive complexes are always close to ~3.5 Å for both (–)- and (+)-cocaine no matter whether the X-ray crystal structure or homology model of BChE was used as the starting structure. The similar computational results obtained from the use of the X-ray crystal structure and homology model of BChE provides evidence that the fundamental structural and mechanistic insights obtained from the previous computational studies of Zhan et al are reliable, despites the previous simulations were performed by using the homology model when the X-ray crystal structure was not available.

Further, the simulated structures of the non-prereactive 15 BChE-cocaine complexes were superimposed with the corresponding prereactive complexes. As shown in FIG. 3, the (–)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex is hindered by some residues as the positions of Y332, A328, and F329 20 residues in the non-prereactive complex are significantly different from the corresponding positions in the prereactive complex, whereas none of these residues hinders the (+)-cocaine rotation in the BChE active site from the non-prereactive complex to the prereactive complex because these residues stay in nearly the same positions in the two BChE-(+)-cocaine complexes.

(-)-cocaine binding with BChE mutants. Now that the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex has been known to be the rate-determining step of the BChE-catalyzed hydrolysis of (-)-cocaine as shown by Zhan et al, useful BChE mutants should be designed to specifically accelerate the change from the non-prereactive BChE-(-)-cocaine complex to the prereactive complex. The question is whether MD simulation can be 35 performed to help design BChE mutants that have higher catalytic activity for (-)-cocaine hydrolysis.

In the simulated non-prereactive complex, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O² is 7.6 Å for A328W/Y332A BChE and 7.1 Å for 40 A328W/Y332G BChE, as seen in Table 2 above. In the simulated prereactive complex, the average values of this important internuclear distance become 3.87 and 3.96 Å for A328W/Y332A and A328W/Y332G BChE's, respectively. Compared to the simulated wild-type BChE-(-)-cocaine pre- 45 reactive complex, the average distances between the carbonyl carbon of the cocaine benzovl ester and S198 O² in the prereactive complex of (-)-cocaine with A328W/Y332A and A328W/Y332G BChE's are all slightly longer, whereas the average distances between the carbonyl oxygen of the 50 cocaine benzoyl ester and the NH of G116, G117, and A199 residues are all shorter. This provides evidence that (-)-cocaine more strongly bind with A328W/Y332A and A328W/ Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/ 55 Y332A and A328W/Y332G BChE's from the nonprereactive complex to the prereactive complex did not cause considerable changes of the positions of A332 (or G332), W328, and F329 residues as seen in FIG. 4, compared to the (-)-cocaine rotation in the active site of wild-type BChE. 60 These results provide evidence that A328W/Y332A and A328W/Y332G BChE's should be associated with lower energy barriers than the wild-type for the (-)-cocaine rotation from the non-prereactive complex to the prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is 65 very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine

rotation was significant only in A328W/Y332A BChE, thus suggesting that the energy barrier for the (–)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE.

18

Concerning (-)-cocaine binding with A328W/Y332A/ Y419S BChE, Y419 stays deep inside the protein and does not directly contact with the cocaine molecule. The Y419S mutation was tested because it was initially expected that this mutation would further increase the free space of the active site pocket so that the (-)-cocaine rotation could be easier. However, as seen in Table 2 above, the average distance between the carbonyl carbon of cocaine benzoyl ester and S198 O? atom in the simulated prereactive complex was as long as 5.84 Å. The average distances between the carbonyl oxygen of the cocaine benzoyl ester and the NH hydrolysis atoms of G116, G117, and A199 residues are between 4.56 and 6.97 Å; no any hydrogen bond between them. In addition to the internuclear distances, another interesting geometric parameter is the dihedral angle, T, formed by S198 O² and the plane of the carboxylate group of the cocaine benzovl ester. As seen in Table 2, the T values in the prereactive complexes of cocaine with wild-type BChE and all of the BChE mutants other than A328W/Y332A/Y419S BChE all slightly deviate from the ideal value of 900 for the nucleophilic attack of S198 O? at the carbonyl carbon of cocaine. The T value in the prereactive complex of (-)-cocaine with A328W/Y332A/ Y419S BChE is 164°, which is considerably different from the ideal value of 90°.

Catalytic activity. The aforementioned discussion provides evidence that the energy barriers for the (-)-cocaine rotation in A328W/Y332A and A328W/Y332G BChE's from the non-prereactive complex to the prereactive complex, the ratedetermining step for the BChE-catalyzed hydrolysis of (-)cocaine, should be lower than that in the wild-type BChE. Thus, the MD simulations predict that both A328W/Y332A and A328W/Y332G BChE's should have a higher catalytic activity than the wild-type BChE for (-)-cocaine hydrolysis. Further, the MD simulations also suggest that the energy barrier for the (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE and, therefore, the catalytic activity of A328W/Y332G BChE for the (-)-cocaine hydrolysis should be slightly higher than the activity of A328W/Y332A BChE. In addition, the MD simulations predict that A328W/Y332A/Y419S BChE should have no catalytic activity, or have a considerably lower catalytic activity than the wild-type, for (-)-cocaine hydrolysis because (-)-cocaine binds with the mutant BChE in a way that is not suitable for the catalysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported to be 8.56×10^6 M min⁻¹, which is 9.39 times of the k_{cat}/K_M value (9.11×10⁵ M min¹) of the wild-type BChE. To examine these theoretical predictions of the relative activity for A328W/Y332G and A328W/Y332A/Y419SBChE's, a A328W/Y332A, A328W/ Y332G, and A328W/Y332A/Y419S BChE was produced through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with all of three mutants under the same condition and compared the catalytic efficiency of the A328W/Y332G and A328W/Y332A/Y419S to that of the A328W/Y332A for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured timedependent radiometric data, the ratio of the k_{cat}/K_M value of A328W/Y332G BChE to the k_{cat}/K_M value of A328W/ Y332A BChE for the (-)-cocaine hydrolysis was determined to be ~2.08, or A328W/Y332G BChE has a k_{cat}/K_M value of $\sim 1.78 \times 10^7$ M min⁻¹ for the (-)-cocaine hydrolysis. The radio-

metric data show no significant catalytic activity for A328W/Y332A/Y419S BChE. These experimental data are consistent with the theoretical predictions based on the MD simulations.

Conclusion. Molecular modeling, molecular docking, and 5 molecular dynamics (MD) simulations were performed to study cocaine binding with human butyrylcholinesterase (BChE) and its mutants, based on a recently reported X-ray crystal structure of human BChE. The MD simulations of cocaine binding with wild-type BChE led to average BChEcocaine binding structures similar to those obtained recently from the MD simulations based on a homology model of BChE, despite the significant difference found at the acyl binding pocket. This confirms the fundamental structural and 15 mechanistic insights obtained from the prior computational studies of Zhan et al based on a homology model of BChE, e.g., the rate-determining step for BChE-catalyzed hydrolysis of biologically active (-)-cocaine is the (-)-cocaine rotation in the BChE active site from the non-prereactive BChE-(-)cocaine complex to the prereactive complex.

The MD simulations further reveal that the (-)-cocaine rotation in the active site of wild-type BChE from the nonprereactive complex to the prereactive complex is hindered by some residues such that the positions of Y332, A328, and F329 residues in the non-prereactive complex are significantly different from those in the prereactive complex. Compared to (-)-cocaine binding with wild-type BChE, (-)-cocaine more strongly bind with A328W/Y332A and A328W/ Y332G BChE's in the prereactive complexes. More importantly, the (-)-cocaine rotation in the active site of A328W/Y332A and A328W/Y332G BChE's from the nonprereactive complex to the prereactive complex did not cause 35 considerable changes of the positions of A332 or G332, W328, and F329 residues. These results provide evidence that A328W/Y332A and A328W/Y332G BChE's are associated with lower energy barriers than wild-type BChE for the (-)cocaine rotation from the non-prereactive complex to the $^{\,40}$ prereactive complex. Further, (-)-cocaine binding with A328W/Y332G BChE is very similar to the binding with A328W/Y332A BChE, but the position change of F329 residue caused by the (-)-cocaine rotation was significant only in

20

A328W/Y332A BChE, thus suggesting that the energy barrier for (-)-cocaine rotation in A328W/Y332G BChE should be slightly lower than that in A328W/Y332A BChE. It has also been demonstrated that (-)-cocaine binds with A328W/Y332A/Y419S BChE in a way that is not suitable for the catalysis.

Based on the computational results, both A328W/Y332A and A328W/Y332G BChE's have catalytic activity for (-)-cocaine hydrolysis higher than that of wild-type BChE and the activity of A328W/Y332G BChE should be slightly higher than that of A328W/Y332A BChE, whereas A328W/Y332A/Y419S BChE is expected to lose the catalytic activity. The computational predictions are completely consistent with the experimental kinetic data, providing evidence that the used computational protocol, including molecular modeling, molecular docking, and MD simulations, is reliable in prediction of the catalytic activity of BChE mutants for (-)-cocaine hydrolysis.

Experiment 2

MD Simulations and Quantum
Mechanical/Molecular Mechanical (QM/MM)
Calculations Relating to a 199S/A328W/Y332G
Mutant (Mutant 1) (SEQ ID NO: 1).

Generally speaking, for rational design of a mutant enzyme with a higher catalytic activity for a given substrate, one needs to design a mutation that can accelerate the rate-determining step of the entire catalytic reaction process while the other steps are not slowed down by the mutation. Reported computational modeling and experimental data indicated that the formation of the prereactive BChE-(-)-cocaine complex (ES) is the rate-determining step of (-)-cocaine hydrolysis catalyzed by wild-type BChE as disclosed by Sun et al, Zhan et al and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. *J. Phys. Chem. B* 2005, 109, 4776, herein incorporated by reference, whereas the rate-determining step of the corresponding (+)-cocaine hydrolysis is the chemical reaction process consisting of four individual reaction steps disclosed by Zhan et al and shown in Scheme 3 and Scheme 4 below.

Scheme 3. Schematic representation of BChE-catalyzed hydrolysis of (–)-cocaine. Only QM-treated high-layer part of the reaction system in the QM/MM calculations are drawn. Notation [H] refers to a non-hydrogen atom in the MM-treated low-layer part of the protein and the cut covalent bond 5 with this atom is saturated by a hydrogen atom. The dash lines in the transition state structures represent the transition bonds.

This mechanistic understanding is consistent with the experimental observation of Sun et al, that the catalytic rate constant of wild-type BChE against (+)-cocaine is pH-dependent, whereas that of the same enzyme against (-)-cocaine is independent of the pH. The pH-dependence of the rate constant for (+)-cocaine hydrolysis is clearly associated with the protonation of H438 residue in the catalytic triad (S198, H438, and E325). For the first and third steps of the reaction process, when H438 is protonated, the catalytic triad cannot function and, therefore, the enzyme becomes inactive. The lower the pH of the reaction solution is, the higher the concentration of the protonated H438 is, and the lower the concentration of the active enzyme is. Hence, the rate constant was found to decrease with decreasing the pH of the reaction solution for the enzymatic hydrolysis of (+)-cocaine.

Based on the above mechanistic understanding, the efforts for rational design of the BChE mutants reported in literature have been focused on how to improve the ES formation 25 process. Indeed, several BChE mutants, including A328W, A328W/Y332A, A328W/Y332G, and F227A/S287G/ A328W/Y332M, have been found to have a significantly higher catalytic efficiency (k_{cat}/K_M) against (-)-cocaine; these mutants of BChE have an approximate 9 to 34-fold 30 improved catalytic efficiency against (-)-cocaine. Experimental observation also indicated that the catalytic rate constant of A328W/Y332A BChE is pH-dependent for both (-)and (+)-cocaine. The pH-dependence reveals that for both (-)- and (+)-cocaine, the rate-determining step of the 35 hydrolysis catalyzed by A328W/Y332A BChE should be either the first or the third step of the reaction process. Further, if the third step were rate determining, then the catalytic efficiency of the A328W/Y332A mutant against (-)-cocaine should be as high as that of the same mutant against (+)- 40 cocaine because the (-)- and (+)-cocaine hydrolyses share the same third and fourth steps (see Scheme 3). However, it has also been observed that the A328W/Y332A mutant only has a ~9-fold improved catalytic efficiency against (-)-cocaine, whereas the A328W/Y332A mutation does not change the 45 high catalytic activity against (+)-cocaine. This analysis of the experimental and computational data available in literature clearly shows that the rate-determining step of (-)-cocaine hydrolysis catalyzed by the A328W/Y332A mutant should be the first step of the chemical reaction process. 50 Further, recently reported computational modeling also suggests that the formation of the prereactive BChE-(-)-cocaine complex (ES) is hindered mainly by the bulky side chain of Y332 residue in wild-type BChE, but the hindering can be removed by the Y332A or Y332G mutation. Therefore, start-55 ing from the A328W/Y332A or A328W/Y332G mutant, the truly rational design of further mutation(s) to improve the catalytic efficiency of BChE against (-)-cocaine should aim to decrease the energy barrier for the first reaction step without significantly affecting the ES formation and other chemi- 60 cal reaction steps.

The following rational design of a high-activity mutant of BChE against (-)-cocaine is based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/MM) calculations

were performed to model the protein environmental effects on the stabilization of the transition-state structure for BChE-catalyzed hydrolysis of (–)-cocaine. The simulated and calculated results indicate that the transition-state structure can be stabilized better by the protein environment in A199S/A328W/Y332G mutant of BChE than that in the wild-type. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/A328W/Y332G mutant against (–)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/A328W/Y332G mutant has a significantly improved catalytic efficiency against (–)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against (–)-cocaine.

24

MD simulations. It should be stressed that a critical issue exists with regard to any MD simulation on a transition state. In principle, MD simulation using a classical force field (molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface. Hence, MD simulation using a classical force field cannot directly simulate a transition state without any restraint on the geometry of the transition state. Nevertheless, if one can technically remove the freedom of imaginary vibration in the transition state structure, then the number of vibrational freedoms (normal vibration modes) for a nonlinear molecule will decrease from 3N-6. The transition state structure is associated with a local minimum on the potential energy surface within a subspace of the reduced vibrational freedoms, although it is associated with a firstorder saddle point on the potential energy surface with all of the 3N-6 vibrational freedoms. Theoretically, the vibrational freedom associated with the imaginary vibrational frequency in the transition state structure can be removed by appropriately freezing the reaction coordinate. The reaction coordinate corresponding to the imaginary vibration of the transition state is generally characterized by a combination of some key geometric parameters. These key geometric parameters are bond lengths of the forming and breaking covalent bonds for BChE-catalyzed hydrolysis of cocaine, as seen in Scheme 3. Thus, one just needs to maintain the bond lengths of the forming and breaking covalent bonds during the MD simulation on a transition state. Technically, one can maintain the bond lengths of the forming and breaking covalent bonds by simply fixing all atoms within the reaction center, by using some constraints on the forming and breaking covalent bonds, or by redefining the forming and breaking covalent bonds. It should be pointed out that the only purpose of performing such type of MD simulation on a transition state is to examine the dynamic change of the protein environment surrounding the reaction center and the interaction between the reaction center and the protein environment. For this study, of interest is the simulated structures, as the total energies calculated in this way are meaningless.

The initial BChE structures used in the MD simulations were prepared based on the previous MD simulation in accordance with Hamza et al on the prereactive ES complex for wild-type BChE with (–)-cocaine in water by using Amber7 program package. The previous MD simulations on the prereactive BChE-(–)-cocaine complex (ES) started from the X-ray crystal structure of Nicolet et al deposited in the Protein Data Bank (pdb code: 1 POP). The present MD simulation on the transition state for the first step (TS1) was performed in such a way that bond lengths of the partially formed and

partially broken covalent bonds in the transition state were all constrained to be the same as those obtained from our previous ab initio reaction coordinate calculations on the model reaction system of wild-type BChE in accordance with Zhan et al. The partially formed and partially broken covalent bonds in the transition state will be called "transition" bonds below, for convenience. A sufficiently long MD simulation with the transition bonds constrained should lead to a reasonable protein environment stabilizing the reaction center in the transition-state structure simulated. Further, the simulated TS1 structure for wild-type BChE with (–)-cocaine was used to build the initial structures of TS1 for the examined BChE mutants with (–)-cocaine; only the side chains of mutated residues needed to be changed.

The partial atomic charges for the non-standard residue

atoms, including cocaine atoms, in the TS1 structures were calculated by using the RESP protocol implemented in the Antechamber module of the Amber7 package following electrostatic potential (ESP) calculations at ab initio HF/6-31G* level using Gaussian03 program known in the art. The geometries used in the ESP calculations came from those obtained from the previous ab initio reaction coordinate calculations of Zhan et al, but the functional groups representing the oxyanion hole were removed. Thus, residues G116, G117, and 25 A199 were the standard residues as supplied by Amber7 in the MD simulations. The general procedure for carrying out the MD simulations in water is essentially the same as that used in our previously reported other computational studies including Zhan et al, Hamza et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 1999, 121, 7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. L. J. Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, 35 R. L. J. Comput. Chem. 2003, 24, 368, (d) Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. Bioorg. Med. Chem. 2005, 13, 4544, herein all incorporated by reference. Each aforementioned starting TS1 structure was neutralized by adding chloride counterions and was solvated in a rectangular box of TIP3P water molecules with a minimum solute-wall distance of 10 Å as described by Jorgensen, W. L.; Chandrasekhar, J.; Madura, J.; Klein, M. L. J. Chem. Phys. 1983, 79, 926, herein incorporated by reference. The total numbers of atoms in the 45 solvated protein structures for the MD simulations are nearly 70,000, although the total number of atoms of BChE and (-)-cocaine is only 8417 (for the wild-type BChE). All of the MD simulations were performed by using the Sander module of Amber7 package. The solvated systems were carefully equilibrated and fully energy minimized. These systems were gradually heated from T=10 K to T=298.15 K in 30 ps before running the MD simulation at T=298.15 K for 1 ns or longer, making sure that a stable MD trajectory was obtained for each 55 of the simulated TS1 structures. The time step used for the MD simulations was 2 fs. Periodic boundary conditions in the NPT ensemble at T=298.15 K with Berendsen temperature coupling and P=1 atm with isotropic molecule-based scaling were applied. The SHAKE algorithm was used to fix all covalent bonds containing hydrogen atoms. The non-bonded pair list was updated every 10 steps. The particle mesh Ewald (PME) method in accordance with Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen, L. G. J. 65 Chem. Phys. 1995, 98, 10089, herein incorporated by reference, was used to treat long-range electrostatic interactions. A

26

residue-based cutoff of 10 Å was utilized to the non-covalent interactions. The coordinates of the simulated systems were collected every 1 ps during the production MD stages.

OM/MM calculations. For each TS1 structure examined, after the MD simulation was completed and a stable MD trajectory was obtained, all of the collected snapshots of the simulated structure, excluding those before the trajectory was stabilized, were averaged and further energy-minimized. The energy-minimized average structure (with the transition bonds constrained) was used as an initial geometry to carry out a further geometry optimization by using the ONIOM approach of Dapprich, S.; Komaromi, I.; Byun, K. S.; Morokuma, K.; Frisch, M. J. J. Mol. Struct. (Theochem) 1999, 461, 1-21, herein incorporated by reference, implemented in the Gaussian 03 program of Frisch, M. J. et al Gaussian 03, Revision A.1, Gaussian, Inc., Pittsburgh, Pa., 2003, herein incorporated by reference. Two layers were defined in the present ONIOM calculation: the high layer, as depicted in Scheme 3 above, was calculated quantum mechanically at the ab initio HF/3-21G level, whereas the low layer was calculated molecular mechanically by using the Amber force field as used in our MD simulation and energy minimization with the Amber7 program. The ONIOM calculations at the HF/3-21 G: Amber level in this study are a type of QM/MM calculations of Vreven, T.; Morokuma, K. J. Chem. Phys. 2000, 113, 2969-2975 and Frisch, M.; Vreven, T.; Schlegel, H. B.; Morokuma, K. J. Comput. Chem. 2003, 24, 760-769, herein both incorporated by reference. Previous reaction coordinate calculations with an active site model of wild-type BChE demonstrate that the HF/3-21G level is adequate for the geometry optimization of this enzymatic reaction system shown by Zhan et al, although the final energy calculations for calculating the energy barriers must be carried out at a higher level. As depicted in Scheme 3, for all of these QM/MM calculations, the same part of the enzyme was included in the QMtreated high layer. So, the QM-treated high layer included (-)-cocaine, key functional groups from the catalytic triad (S198, H438, and E325), and the three residues, i.e., G116, G117, and A199 (or S199 for a particular mutant, see Scheme 4), of the possible oxyanion hole, whereas the entire enzyme structure of BChE was included in the MM-treated low laver. A language computer program was developed to automatically generate the input files for the ONIOM calculations following the MD simulations and subsequent energy minimizations in order to make sure that the atom types used for all low-layer atoms are the same as what were used in the Amber 7. During the TS1 geometry optimization using the two-layer ONIOM, the length of a key transition C—O bond was fixed which dominates the reaction coordinate; all of the other transition bond lengths were relaxed. The C and O atoms in the key transition C—O bond are the carbonyl carbon of (–)-cocaine benzoyl ester and the O^γ atom of S198, respectively, according to the previous reaction coordinate calculations with an active site model of wild-type BChE of Zhan et al.

Most of the MD simulations and QM/MM calculations were performed in parallel on an HP supercomputer (Superdome, with 256 shared-memory processors) at the Center for Computational Sciences, University of Kentucky. Some of

the computations were carried out on a 34-processors IBM x335 Linux cluster and SGI Fuel workstations.

Scheme 4. Schematic representation of the first reaction 55 step for (–)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

Experimental materials. Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from Stratagene (La Jolla, Calif.). ³H-(–)-cocaine (50 Ci/mmol) was purchased from 60 PerkinElmer Life Sciences (Boston, Mass.). The expression plasmid pRc/CMV was a gift from Dr. O. Lockridge, University of Nebraska Medical Center (Omaha, Nebr.). All oligonucleotides were synthesized by the Integrated DNA Technologies, Inc. The QIAprep Spin Plasmid Miniprep Kit and 65 Qiagen plasmid purification kit and QIAquick PCR purification kit were obtained from Qiagen (Santa Clarita, Calif.).

Human embryonic kidney 293T/17 cells were from ATCC (Manassas, Va.). Dulbecco's modified Eagle's medium (DMEM) was purchased from Fisher Scientific (Fairlawn, N.J.). Oligonucleotide primers were synthesized by the Integrated DNA Technologies and Analysis Facility of the University of Kentucky. 3, 3', 5,5'-Tetramethylbenzidine (TMB) was obtained from Sigma (Saint Louis, Mo.). Anti-butyryl-cholinesterase (mouse monoclonal antibody, Product # HAH002-01) was purchased from AntibodyShop (Gentofte, Denmark) and Goat anti-mouse IgG HRP conjugate from Zymed (San Francisco, Calif.).

Site-directed mutagenesis, protein expression, and BChE activity assay. Site-directed mutagenesis of human BChE cDNA was performed by using the QuikChange method of 15 Braman et al. Mutations were generated from wild-type human BChE in a pRc/CMV expression plasmid in accordance with (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. M.; Lockridge, O. Biochemistry 1997, 36, 2266, (b) Masson, P.; Xie, W., Froment, M-T.; 20 Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, herein all incorporated by reference. Using plasmid DNA as template and primers with specific base-pair alterations, mutations were made by polymerase chain reaction with Pfu DNA polymerase, for replication fidelity. The PCR product was treated with Dpn I endonuclease to digest the parental DNA template. Modified plasmid DNA was transformed into Escherichia coli, amplified, and purified. The DNA sequences of the mutants were confirmed by DNA sequenc-35 ing. BChE mutants were expressed in human embryonic kidney cell line 293T/17. Cells were grown to 80-90% confluence in 6-well dishes and then transfected by Lipofectamine 2000 complexes of 4 µg plasmid DNA per each well. Cells were incubated at 37° C. in a CO₂ incubator for 24 hours and 40 cells were moved to 60-mm culture vessel and cultured for four more days. The culture medium [10% fetal bovine serum in Dulbecco's modified Eagle's medium (DMEM)] was harvested for a BChE activity assay. To measure (-)-cocaine and benzoic acid, the product of (-)-cocaine hydrolysis catalyzed by BChE, sensitive radiometric assays were used based on toluene extraction of [³H]-(-)-cocaine labeled on its benzene ring in accordance with Sun et al. In brief, to initiate the enzymatic reaction, 100 nCi of [³H]-(-)-cocaine was mixed with 100 µl of culture medium. The enzymatic reactions 50 proceeded at room temperature (25° C.) for varying time. The reactions were stopped by adding 300 µl of 0.02 M HCl, which neutralized the liberated benzoic acid while ensuring a positive charge on the residual (-)-cocaine. [3H]benzoic acid was extracted by 1 ml of toluene and measured by scintillation counting. Finally, the measured time-dependent radiometric data were fitted to the kinetic equation so that the catalytic efficiency (k_{cat}/K_M) was determined along with the use of an enzyme-linked immunosorbent assay (ELISA) described below.

Enzyme-linked immunosorbent assay (ELISA). The ELISA buffers used in the present study are the same as those described in the literature such as (a) Brock, A.; Mortensen, V.; Loft, A. G. R.; Nergaard-Pedersen, B. J. Clin. Chem. Clin. Biochem. 1990, 28, 221-224, (b) Khattab, A. D.; Walker, C. H.; Johnston, G.; Siddiqui, M. K. Saphier, P. W. Environmental Toxicology and Chemistry 1994, 13, 1661-1667, herein both incorporated by reference. The coating buffer was 0.1 M

sodium carbonate/bicarbonate buffer, pH 9.5. The diluent buffer (EIA buffer) was potassium phosphate monobasic/ potassium phosphate monohydrate buffer, pH 7.5, containing 0.9% sodium chloride and 0.1% bovine serum albumin. The washing buffer (PBS-T) was 0.01 M potassium phosphate 5 monobasic/potassium phosphate monohydrate buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All the assays were performed in triplicate. Each well of an ELISA microtiter plate was filled with 100 µl of the mixture buffer consisting of 20 μl culture medium and 80 μl coating buffer. The plate was covered and incubated overnight at 4° C. to allow the antigen to bind to the plate. The solutions were then removed and the wells were washed four times with PBS-T. The washed wells were filled with 200 µl diluent buffer and kept shaking for 1.5 h at room temperature (25° C.). After washing with PBS-T for 15 four times, the wells were filled with 100 µl antibody (1:8000) and were incubated for 1.5 h, followed by washing for four times. Then, the wells were filled with 100 µl goat anti-mouse IgG HRP conjugate complex diluted to a final 1:3000 dilution, and were incubated at room temperature for 1.5 h, fol- 20 lowed by washing for four times. The enzyme reactions were started by addition of 100 µl substrate (TMB) solution. The reactions were stopped after 15 min by the addition of $100 \,\mu l$ of 2 M sulfuric acid, and the absorbance was read at 460 nm using a Bio-Rad ELISA plate reader.

Hydrogen bonding revealed by the MD simulations. In accordance with one aspect of the present invention, namely the generation of high-activity mutants of BChE against (–)-cocaine, the present invention includes predicting some possible mutations that can lower the energy of the transition 30 state for the first chemical reaction step (TS1) and, therefore, lower the energy barrier for this critical reaction step. Apparently, a mutant associated with the stronger hydrogen bonding between the carbonyl oxygen of (–)-cocaine benzoyl ester and the oxyanion hole of the BChE mutant in the TS1 structure may potentially have a more stable TS1 structure and, therefore, a higher catalytic activity for (–)-cocaine hydrolysis. Hence, the hydrogen bonding with the oxyanion hole in

30

the TS1 structure is a crucial factor affecting the transition state stabilization and the catalytic activity. The possible effects of some mutations on the hydrogen bonding were examined by performing MD simulations and QM/MM calculations on the TS1 structures for (–)-cocaine hydrolysis catalyzed by the wild-type and various mutants BChE's.

The MD simulation in water was performed for 1 ns or longer to make sure a stable MD trajectory was obtained for each simulated TS1 structure with the wild-type or mutant BChE. The MD trajectories actually became stable quickly, so were the H—O distances involved in the potential hydrogen bonds between the carbonyl oxygen of (–)-cocaine and the oxyanion hole of BChE.

Depicted in FIG. 5 are plots of four important H O distances in the MD-simulated TS1 structure versus the simulation time for (-)-cocaine hydrolysis catalyzed by A328W/ Y332A or A199S/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain which exists only in A199S/A328W/Y332G BChE. RMSD represents the root-mean-square deviation (in A) of the simulated positions of the protein backbone atoms from those in the initial structure. The H O distances in the simulated TS1 structures corresponding to the wild-type BChE and the two mutants are summarized in Table 3. The H—O distances between the carbonyl oxygen of (-)-cocaine and the peptidic NH hydrogen atoms of G116, G17, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 2 and FIG. 1. D4 in Table 3 and FIG. 5 refers to the H—O distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 structure corresponding to the A199S/A328W/Y332G mutant, mutant (1) (SEQ ID NO: 2).

TABLE 3

Summary of the MD-simulated and QM/MM-optimized key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).

			Distan	ce ^a	
Transition State	Method	D1	D2	D3	D4 Total HBE ^b
TS1 for (-)-cocaine	MD Average	4.59	2.91	1.92	-5.5 (-4.6)
hydrolysis catalyzed	Maximum	5.73	4.14	2.35	
by wild-type BChE	Minimum	3.35	1.97	1.61	
	Fluctuation	0.35	0.35	0.12	
	QM/MM	4.10	2.21	2.05	-4.2
TS1 for (-)-cocaine	MD Average	3.62	2.35	1.95	-6.2 (-4.9)
hydrolysis catalyzed	Maximum	4.35	3.37	3.02	
by A328W/Y332A	Minimum	2.92	1.78	1.61	
mutant of BChE	Fluctuation	0.23	0.27	0.17	
	QM/MM	3.39	2.05	2.47	-3.3
TS1 for (-)-cocaine	MD Average	5.30	2.21	1.94	2.15 -9.7 (-7.4)
hydrolysis catalyzed	Maximum	6.08	3.06	2.47	3.27
by A199S/A328W/	Minimum	4.57	1.71	1.66	1.56

TABLE 3-continued

Summary of the MD-simulated and QM/MM-optimized key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).

			Distan		
Transition State	Method	D1	D2	D3	D4 Total HBE ^b
Y332G mutant of BChE	Fluctuation QM/MM	0.22 4.83	0.20 2.09	0.13 1.91	0.29 2.59 -7.46

^aD1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #199 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/A328W/Y332G mutant.

^bThe total HBE value under MD is the average of the HBE values calculated by using the

^bThe total HBE value under MD is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in parenthesis is the total HBE value calculated by using the MD-simulated average distances. The total HBE value under QM/MM was evaluated by using the OM/MM-optimized distances.

As seen in Table 3, the simulated H—O distance D1 is always too long for the peptidic NH of G116 to form a N—H—O hydrogen bond with the carbonyl oxygen of (-)cocaine. In the simulated TS1 structure corresponding to 25 wild-type BChE, the carbonyl oxygen of (-)-cocaine formed a firm N—H—O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H O distance was 1.61 to 2.35 Å, with an average value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial 30 N-H-O hydrogen bond with the peptidic NH hydrogen atom of G117 residue; the simulated HO distance was 1.97 to 4.14 Å (the average value: 2.91 Å). In the simulated TS1 structure corresponding to the A328W/Y332A mutant, the simulated average H—O distances with the peptidic NH 35 hydrogen of G117 and A199 are 2.35 and 1.95 Å, respectively. These distances suggest a slightly weaker N—H—O hydrogen bond with A199, but a stronger N-H-O hydrogen bond with G117, in the simulated TS1 structure corresponding to the A328W/Y332A mutant. The overall strength 40 of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A mutant.

However, the story for the simulated TS1 structure associ- 45 ated with the A199S/A328W/Y332G mutant was remarkably different. As one can see from Scheme 4, FIG. 5, and Table 3, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogenbond to the carbonyl oxygen of (-)-cocaine to form an 50 O—H—O hydrogen bond, in addition to the two N—H—O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H-O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.21, 1.94, and 2.15 Å, 55 respectively. Due to the additional O—H—O hydrogen bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/A328W/Y332G BChE should be significantly stronger than that of the wild-type and A328W/Y332A BChE's

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (–)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated H—O distance was estimated by using the empirical HBE equation 65 implemented in AutoDock 3.0 program suite in accordance with (a) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey,

R.; Hart, W. E.; Belew. R. K.; Olson, A. J. J. Comput. Chem. 1998, 19, 1639-1662, and based on the general HBE equation, HBE(r) $\approx 5\epsilon r_0^{12}/r^{12} - 6\epsilon r_0^{10}/r^{10}$, in which r is the H—O distance in the considered hydrogen bond and r₀ is the minimum value of the H—O distance for which the HBE equation can be used. For the calculation, r₀=1.52 Å, because it is the shortest H—O distance found in all of our MD simulations. The ϵ value was determined by using the condition that HBE (r)=-5.0 kcal/mol when r=1.90 Å, herein incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydrogen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in each simulated TS1 structure is given in Table 3.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H—O distance. As seen in Table 3. the total hydrogen-bonding energies (i.e., -4.6, -4.9, and -7.4 kcal/mol for the wild-type, A328W/Y332A, and A199S/ A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total hydrogen-bonding energies (i.e., -5.5, -6.2, and -9.7 kcal/mol) estimated in the aforementioned way. However, the two sets of total HBE values are qualitatively consistent in terms of the relative hydrogen-bonding strengths in the three simulated TS1 structures. In particular, the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/A328W/Y332G BChE is significantly higher than that for the wild-type and A328W/ Y332A BChE's.

Hydrogen bonding based on the QM/MM calculations. The above conclusion obtained from the MD simulations was further examined by carrying out QM/MM calculations.

60 Although this enzymatic reaction system is too large to calculate the QM/MM force constant matrix required in the automated search for a first-order saddle point corresponding to TS1, a partial geometry optimization was performed by fixing the length of the transition C—O bond between the carbonyl carbon of (–)-cocaine and the O atom of S198 in the QM/MM calculation. This transition C—O bond length dominates the reaction coordinate, according to the previous

first-principle reaction coordinate calculations, in accordance with Zhan et al, with an active model of wild-type BChE. In the partial geometry optimization, the transition C—O bond length was fixed at that in the TS1 geometry optimized previously by performing the first-principle reaction coordinate 5 calculation with an active site model of wild-type BChE. This partially optimized geometry should be close to the precisely defined TS1 geometry associated with a first-order saddle point on the potential energy surface, particularly for the hydrogen bonding between the carbonyl oxygen of (–)-co-caine and the oxyanion hole of BChE.

The QM/MM results summarized in Table 3 demonstrate two hydrogen bonds in each of the QM/MM-optimized TS1 structures. Specifically, D2=2.21 Å and D3=2.05 Å in the optimized TS1 structure for wild-type BChE; D2=2.05 Å and D3=2.47 Å in the optimized TS1 structure for the A328W/ Y332A mutant; D2=2.09 Å, D3=1.91 Å, and D4=2.59 Å in the optimized TS1 structure for the A199S/A328W/Y332G mutant. Although the QM/MM-optimized individual H—O distances and the estimated HBE values are different from the 20 corresponding values for individual hydrogen bonds, the relative total HBE values (i.e., -4.2, -3.3, and -7.46 kcal/mol for the wild-type, A328W/Y332A, and A199S/A328W/Y332G BChE's, respectively) estimated from these optimized distances are qualitatively consistent with the corresponding 25 total HBE values (i.e., -4.6, -4.9, and -7.4 kcal/mol) estimated from the MD-simulated average H—O distances.

It should be pointed out that the absolute HBE values estimated in this study are not expected to be accurate, as different computational approaches led different HBE values. 30 Nevertheless, for the purpose of our computational design of a high-activity mutant of BChE, one only needs to know the relative strength of the hydrogen bonding based on the estimated relative total HBE values of different mutants. The three sets of total HBE values (Table 3) estimated from the 35 MD-simulated and QM/MM-optimized H—O distances all consistently demonstrate: (1) the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE should be close to that in 40 the TS1 structure for (-)-cocaine hydrolysis catalyzed by wild-type BChE; (2) the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stron- 45 ger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A328W/Y332A BChE.

Catalytic activity. The computational results discussed above suggest that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the 50 A199S/A328W/Y332G mutant should be significantly more stable than that by the A328W/Y332A mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis 55 of the literature, namely Sun et al and Hamza et al, also indicate that the first chemical reaction step associated with TS1 should be the rate-determining step of (-)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive 60 enzyme-substrate complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This provides evidence of a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A and A199S/A328W/Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, both the MD simu-

lations and QM/MM calculations predict that A199S/A328W/Y332G BChE should have a higher catalytic activity than A328W/Y332A BChE for (–)-cocaine hydrolysis.

34

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported by Sun et al to be $\sim 8.6 \times 10^6$ M min⁻¹, which is ~ 9.4 times of the k_{cat}/K_M value (~9.1×10⁵ M min⁻¹) of wild-type BChE. To examine the theoretical prediction of the higher catalytic activity for A199S/A328W/Y332G BChE, A328W/Y332A and A199S/ A328W/Y332G mutants of BChE were produced through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/A328W/Y332G BChE's to that of the wild-type for (-)-cocaine hydrolysis at benzoyl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the k_{cat}/K_M value of A328W/Y332A BChE to the $k_{\it cat}/K_{\it M}$ value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of the k_{cat}/K_M value of A199S/A328W/Y332G BChE to the k_{cat}/K_M value of A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be \sim 7.2. These data indicate that the ratio of the k_/K_ $_{M}$ value of A199S/A328W/Y332G BChE to the k $_{cat}$ /K $_{M}$ value of wild-type BChE for (-)-cocaine hydrolysis should be $\sim 7.2 \times 8.6 = \sim 62$ or $\sim 7.2 \times 9.4 = \sim 68$. Thus, A199S/A328W/ Y332G BChE has a \sim (65±6)-fold improved catalytic efficiency against (-)-cocaine compared to the wild-type, or A199S/A328W/Y332G BChE has a k_{cat}/K_M value of \sim (5.9±0.5)×10 M min⁻¹ for (–)-cocaine hydrolysis.

Very recently reported F227A/S287G/A328W/Y332M BChE (i.e., AME-359, $k_{car}/K_{M}=3.1\times10^{7}\,\mathrm{M\,min^{-1}}$) has a ~34-fold improved catalytic efficiency for (–)-cocaine hydrolysis. AME-359 has the highest catalytic efficiency against (–)-cocaine within all of the BChE mutants reported in literature prior to the present study. The catalytic efficiency for our A199S/A328W/Y332G BChE is about two times of that for AME-359 against (–)-cocaine.

Conclusion. Molecular dynamics (MD) simulations and hybrid quantum mechanical/molecular mechanical (QM/ MM) calculations on the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) mutants lead to a better understanding of the effects of protein environment on the transition state stabilization. All of the computational results consistently demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)-cocaine hydrolysis catalyzed by the wildtype and A328W/Y332A BChE's. Thus, both the MD simulations and QM/MM calculations predict that A199S/ A328W/Y332G BChE should have a lower energy barrier for the chemical reaction process and, therefore, a higher catalytic efficiency (k_{cat}/K_M) for (-)-cocaine hydrolysis; A328W/ Y332A BChE has been known to have a ~9-fold improved catalytic efficiency for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimental tests showing a ~(65±6)-fold improved catalytic efficiency for A199S/A328W/Y332G BChE against (-)-cocaine compared to the wild-type BChE. The k_{cat}/K_M value determined for A199S/A328W/Y332G BChE is about two times of the k /

K_M value for F227A/S287G/A328W/Y332M BChE (i.e., AME-359, which has the highest catalytic efficiency within all BChE mutants reported prior to the present study) against (–)-cocaine. The encouraging outcome of this study suggests that the transition-state modeling is a promising approach for rational design of high-activity mutants of BChE as a therapeutic treatment of cocaine abuse.

Experiment 3

MD Simulation and Generation of Mutant A199S/S287G/A328W/Y332G BCHE (Mutant 3) (SEQ ID NO: 14).

The following simulation and mutant generation relate to 15 A199S/S287G/A328W/Y332G (mutant 3) as a rational design of a high-activity mutant of BChE against (-)-cocaine based on detailed computational modeling of the transition state for the rate-determining step (i.e., the first step of the chemical reaction process). Molecular dynamics (MD) simu- 20 lations were performed to model the protein environmental effects on the stabilization of the transition-state structure for BChE-catalyzed hydrolysis of (-)-cocaine as described above for mutant A199S/A328W/Y332G (mutant 1). The simulated results indicate that the transition-state structure 25 can be stabilized much better by the protein environment in A199S/S287G/A328W/Y332G BChE than that in wild-type BChE and in other BChE mutants examined. The computational modeling led to a prediction of the higher catalytic efficiency for the A199S/S287G/A328W/Y332G mutant 30 against (-)-cocaine. The prediction has been confirmed by wet experimental tests showing that the A199S/S287G/ A328W/Y332G mutant has a remarkably improved catalytic efficiency against (-)-cocaine. All of the obtained results clearly demonstrate that directly modeling the transition-state 35 structure provides a reliable computational approach to the rational design of a high-activity mutant of BChE against

MD simulations. As with the A199S/A328W/Y332G mutant, when performing any MD simulation on a transition 40 state, in principle, MD simulation using a classical force field

36

(molecular mechanics) can only simulate a stable structure corresponding to a local minimum on the potential energy surface, whereas a transition state during a reaction process is always associated with a first-order saddle point on the potential energy surface.

The initial BChE structures used in the MD simulations were prepared based on our previous MD simulation as above with the prior mutant and the prereactive BChE-(-)-cocaine complex (ES) started from the X-ray crystal structure deposited in the Protein Data Bank (pdb code: 1 POP).

The general procedure for carrying out the MD simulations in water is essentially the same as that used in the computational studies for mutant A199S/A328W/Y332G (mutant 1). Site-directed mutagenesis of human BChE cDNA was performed as described before.

The MD simulation in water was performed as described above, on this mutant. Depicted in FIG. 6 are plots of four important H—O distances in the MD-simulated TS1 structure versus the simulation time for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE, along with the root-mean-square deviation (RMSD) of the simulated positions of backbone atoms from those in the corresponding initial structure. Traces D1, D2, and D3 refer to the distances between the carbonyl oxygen of (-)-cocaine and the NH hydrogen of G116, G117, and S199, respectively. Trace D4 is the internuclear distance between the carbonyl oxygen of (-)-cocaine and the hydroxyl hydrogen of the S199 side chain in A199S/S287G/A328W/Y332G BChE (mutant 3). RMSD represents the root-mean-square deviation (in Å) of the simulated positions of the protein backbone atoms from those in the initial structure.

The H—O distances in the simulated TS1 structures for wild-type BChE and its three mutants are summarized in Table 4. The H—O distances between the carbonyl oxygen of (–)-cocaine and the peptidic NH hydrogen atoms of G116, G117, and A199 (or S199) of BChE are denoted by D1, D2, and D3, respectively, in Table 4 and FIG. 6 refers to the H—O distance between the carbonyl oxygen of (–)-cocaine and the hydroxyl hydrogen of S199 side chain in the simulated TS1 structure corresponding to the A199S/S287G/A328W/Y332G mutant.

TABLE 4

Summary of the MD-simulated key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (–)-cocaine benzoyl ester in the first transition state (TS1).

Transition State		D1	D2	D3	D4	Total HBE ^b
TS1 structure for (-)-cocaine	Average	4.59	2.91	1.92		-5.5 (-4.6)
hydrolysis catalyzed by	Maximum	5.73	4.14	2.35		
wild-type BChE	Minimum	3.35	1.97	1.61		
	Fluctuation	0.35	0.35	0.12		
TS1 structure for (-)-cocaine	Average	3.62	2.35	1.95		-6.2 (-4.9)
hydrolysis catalyzed by	Maximum	4.35	3.37	3.02		
A328W/Y332A mutant of BChE	Minimum	2.92	1.78	1.61		
	Fluctuation	0.23	0.27	0.17		
TS1 structure for (-)-cocaine	Average	3.60	2.25	1.97		-6.4 (-5.0)
hydrolysis catalyzed by	Maximum	4.24	3.17	2.76		
A328W/Y332G mutant of	Minimum	2.89	1.77	1.62		
BChE	Fluctuation	0.23	0.24	0.17		
TS1 structure for (-)-cocaine	Average	4.39	2.60	2.01	1.76	-14.0 (-12.0)
hydrolysis catalyzed by	Maximum	5.72	4.42	2.68	2.50	

TABLE 4-continued

Summary of the MD-simulated key distances (in Å) and the calculated total hydrogen-bonding energies (HBE, in kcal/mol) between the oxyanion hole and the carbonyl oxygen of (-)-cocaine benzoyl ester in the first transition state (TS1).

		Distance ^a										
Transition State		D1	D2	D3	D4	Total HBE ^b						
A199S/S287G/A328W/Y332G mutant of BChE	Minimum Fluctuation	2.07	1.76 0.36	1.02	1.48 0.12							

aD1, D2, and D3 represent the internuclear distances between the carbonyl oxygen of cocaine benzoyl ester and the NH hydrogen of residues #116 (i.e., G116), #117 (i.e., G117), and #199 (i.e., A199 or S199) of BChE, respectively. D4 is the internuclear distance between the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen of S199 side chain in the A199S/S287G/A328W/Y332G mutant.

b The total HBE value is the average of the HBE values calculated by using the instantaneous dis-

^oThe total HBE value is the average of the HBE values calculated by using the instantaneous distances in all of the snapshots. The value in parenthesis is the total HBE value calculated by using the MD-simulated average distances.

As seen in Table 4, the simulated H—O distance D1 is always too long for the peptidic NH of G116 to form a N—H—O hydrogen bond with the carbonyl oxygen of (-)cocaine in all of the simulated TS1 structures. In the simulated TS1 structure for wild-type BChE, the carbonyl oxygen of 25 (-)-cocaine formed a firm N—H, O hydrogen bond with the peptidic NH hydrogen atom of A199 residue; the simulated H O distance (D2) was 1.61 to 2.35 Å, with an average D2 value of 1.92 Å. Meanwhile, the carbonyl oxygen of (-)-cocaine also had a partial N—H—O hydrogen bond with the peptidic 30 NH hydrogen atom of G117 residue; the simulated H—O distance (D3) was 1.97 to 4.14 Å (the average D3 value: 2.91 Å). The average D2 and D3 values became 2.35 and 1.95 Å, respectively, in the simulated TS1 structure for the A328W/ Y332A mutant. These distances suggest a slightly weaker 35 N—H—O hydrogen bond with A199, but a stronger N—H—O hydrogen bond with G117, in the simulated TS1 structure for the A328W/Y332A mutant that the corresponding N—H—O hydrogen bonds for the wild-type. The average D2 and D3 values (2.25 and 1.97 Å, respectively) in the 40 simulated TS1 structure for the A328W/Y332G mutant are close to the corresponding distances for the A328W/Y332A

mutant. The overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme is not expected to change considerably when wild-type BChE is replaced by the A328W/Y332A or A328W/Y332G mutant.

However, the story for the simulated TS1 structure for the A199S/S287G/A328W/Y332G mutant was remarkably different. As one can see from Scheme 5, FIG. 6, and Table 4, when residue #199 becomes a serine (i.e., S199), the hydroxyl group on the side chain of S199 can also hydrogenbond to the carbonyl oxygen of (-)-cocaine to form an O—H—O hydrogen bond, in addition to the two N—H—O hydrogen bonds with the peptidic NH of G117 and S199. The simulated average H—O distances with the peptidic NH hydrogen of G117, peptidic NH hydrogen of S199, and hydroxyl hydrogen of S199 are 2.60, 2.01, and 1.76 Å, respectively. Due to the additional O—H—O hydrogen bond, the overall strength of the hydrogen bonding with the modified oxyanion hole of A199S/S287G/A328W/Y332G BChE should be significantly stronger than that of wild-type, A328W/Y332A, and A328W/Y332G BChE's.

Scheme 5. Schematic representation of the transition-state structure for first reaction step for (-)-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation.

To better represent the overall strength of hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in a MD-simulated TS1 structure, the hydrogen bonding energy (HBE) associated with each simulated H—O distance was estimated by using the empirical HBE equation implemented in AutoDock 3.0 program suite of (a) Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, L. 10 M.; Lockridge, O. Biochemistry 1997, 36, 2266, (b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 1999, 55, 15 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, O. J. Pharmacol. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; Lockridge, O. Eur. J. Biochem. 2002, 269, 630, herein all incorporated by reference. Specifically, for each hydrogen bond with the carbonyl oxygen of (-)-cocaine, a HBE value can be evaluated with each snapshot of the MD-simulated structure. The final HBE of the MD-simulated hydrogen bond is considered to be the average HBE value of all snapshots taken from the stable MD trajectory. The estimated total HBE value for the hydro- 25 gen bonds between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in each simulated TS1 structure is also listed in Table 4.

The HBE for each hydrogen bond was estimated by using the MD-simulated average H—O distance. As seen in Table 4, 30 the total hydrogen-bonding energies (i.e., -4.6, -4.9, -5.0, and -12.0 kcal/mol for the wild-type, A328W/Y332A, A328W/Y332G, and A199S/S287G/A328W/Y332G BChE's, respectively) estimated in this way are systematically higher (i.e., less negative) than the corresponding total 35 hydrogen-bonding energies (i.e., -5.5, -6.2, -6.4, and -14.0kcal/mol) estimated in the aforementioned way. However, the two sets of total HBE values are qualitatively consistent with each other in terms of the relative hydrogen-bonding the two sets of total HBE values consistently reveal that the overall strength of the hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole in the simulated TS1 structure for A199S/S287G/A328W/Y332G BChE is significantly higher than that for wild-type, A328W/ 45 Y332A, and A328W/Y332G BChE's.

Catalytic activity. The computational results discussed above provides evidence that the transition state for the first chemical reaction step (TS1) of (-)-cocaine hydrolysis catalyzed by the A199S/S287G/A328W/Y332G mutant should 50 be significantly more stable than that by the A328W/Y332A or A328W/Y332G mutant, due to the significant increase of the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine and the oxyanion hole of the enzyme in the TS1 structure. The aforementioned analysis of the literature 55 of Sun et al and Hamza et al also indicates that the first chemical reaction step associated with TS1 should be the rate-determining step of (–)-cocaine hydrolysis catalyzed by a BChE mutant including Y332A or Y332G mutation, although the formation of the prereactive enzyme-substrate 60 complex (ES) is the rate-determining step for (-)-cocaine hydrolysis catalyzed by wild-type BChE. This suggests a clear correlation between the TS1 stabilization and the catalytic activity of A328W/Y332A, A328W/Y332G, and A199S/S287G/A328W/Y332G BChE's for (-)-cocaine hydrolysis: the more stable the TS1 structure, the lower the energy barrier, and the higher the catalytic activity. Thus, the

40

MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a higher catalytic activity than A328W/ Y332A or A328W/Y332G BChE for (-)-cocaine hydrolysis.

The catalytic efficiency (k_{cat}/K_M) of A328W/Y332A BChE for (-)-cocaine hydrolysis was reported to be $\sim 8.6 \times 10^6$ M min⁻¹, which is ~9.4 times of the k_{cat}/K_M value (~9.1×10⁵ M min⁻¹) of wild-type BChE for (-)-cocaine hydrolysis. The catalytic efficiency of A328W/Y332G BChE was found to be slightly higher than that of A328W/Y332A BChE for (-)cocaine hydrolysis. To examine the theoretical prediction of the higher catalytic activity for A199S/S287G/A328W/ Y332G BChE, the A328W/Y332A and A199S/S287G/ A328W/Y332G mutants of BChE were produced as previously discussed through site-directed mutagenesis. To minimize the possible systematic experimental errors of the kinetic data, kinetic studies were performed with the two mutants and wild-type BChE under the same condition and compared the catalytic efficiency of A328W/Y332A and A199S/S287G/A328W/Y332G BChE's to that of the wildtype for (-)-cocaine hydrolysis at benzovl ester group. Based on the kinetic analysis of the measured time-dependent radiometric data and the ELISA data, the ratio of the k_{cat}/K_{M} value of A328W/Y332A BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis was determined to be ~8.6. The determined catalytic efficiency ratio of ~8.6 is in good agreement with the ratio of ~9.4 determined by Sun et al. Further, by using the same experimental protocol, the ratio of the $\mathbf{k}_{cat}/\mathbf{K}_{M}$ value of A199S/S287G/A328W/Y332G BChE to the k_{cat}/K_M value of A328W/Y332A BChE for (-)-cocaine hydrolysis was determined to be ~50.6. These data indicate that the ratio of the k_{cat}/K_M value of A199S/S287G/A328W/ Y332G BChE to the k_{cat}/K_M value of wild-type BChE for (-)-cocaine hydrolysis should be \sim 50.6×8.6= \sim 435 or \sim 50.6× 9.4=~476. Thus, A199S/S287G/A328W/Y332G BChE has a ~(456±41)-fold improved catalytic efficiency against (–)-cocaine compared to the wild-type, or A199S/S287G/A328W/ Y332G BChE has a k_{cat}/K_M value of $\sim (4.15\pm0.37)\times 10^8$ M min for (-)-cocaine hydrolysis. The catalytic efficiency of A199S/S287G/A328W/Y332G BChE against (-)-cocaine is strengths in the three simulated TS1 structures. In particular, 40 much higher than that of AME-359 (i.e., F227A/S287G/ A328W/Y332M BChE, $k_{cat}/K_{M}=3.1\times10^{7} \text{ M min}^{1}$:, whose catalytic efficiency against (-)-cocaine is the highest within all of the previously reported BChE mutants) which has a ~34-fold improved catalytic efficiency against (-)-cocaine compared to wild-type BChE.

By using the designed A199S/S287G/A328W/Y332G BChE as an exogenous enzyme in human, when the concentration of this mutant is kept the same as that of the wild-type BChE in plasma, the half-life time of (-)-cocaine in plasma should be reduced from the ~45-90 min to only ~6-12 seconds, considerably shorter than the time required for cocaine crossing the blood-brain barrier to reach CNS. Hence, the outcome of this study could eventually result in a valuable, efficient anti-cocaine medication.

Conclusion. The transition-state simulations demonstrate that the overall hydrogen bonding between the carbonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion hole of BChE in the TS1 structure for (-)-cocaine hydrolysis catalyzed by A199S/S287G/A328W/Y332G BChE should be significantly stronger than that in the TS1 structure for (-)cocaine hydrolysis catalyzed by the wild-type BChE and other BChE mutants simulated. Thus, the MD simulations predict that A199S/S287G/A328W/Y332G BChE should have a significantly lower energy barrier for the chemical reaction process and, therefore, a significantly higher catalytic efficiency (k_{cat}/K_M) for (-)-cocaine hydrolysis. The theoretical prediction has been confirmed by wet experimen-

tal tests showing a ~(456±41)-fold improved catalytic efficiency for A199S/S287G/A328W/Y332G BChE against (–)-cocaine compared to the wild-type BChE. The k_{cat}/K_M value determined for A199S/S287G/A328W/Y332G BChE is much higher than the k_{cat}/K_M value for AME-359 (i.e., 5F227A/S287G/A328W/Y332M BChE, whose catalytic efficiency against (–)-cocaine is the highest within all of the BChE mutants reported previously in literature) which has a ~34-fold improved catalytic efficiency against (–)-cocaine

compared to the wild-type BChE. The outcome of this study provides evidence that the transition-state simulation is a novel and unique approach for rational enzyme redesign and drug discovery.

Although the invention has been described in detail with respect to preferred embodiments thereof, it will be apparent that the invention is capable of numerous modifications and variations, apparent to those skilled in the art, without departing from the spirit and scope of the invention.

SEQUENCE LISTING

<160> NUMBER OF SEO ID NOS: 30 <210> SEO ID NO 1 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-1 mutant A199S/A328W/Y332G of Human butyrylcholinesterase (BChE) <400> SEOUENCE: 1 gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60 tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120 cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 180 tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 240 atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 300 gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360 ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 420 gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 480 gaggetecag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc attetgeaaa gtggtteett taatgeteet tgggeggtaa eatetetta tgaagetagg aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780 atcaaqtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840 ccctatggga ctcctttgtc agtaaacttt ggtccgaccg tggatggtga ttttctcact 900 gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 960 gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 1020 aacaatagta tcataactag aaaagaattt caggaaggtt taaaaaatatt ttttccagga 1080 gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140 agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200 cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 1260 tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320 gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 1380 gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440 aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 1500

ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga

ttct	ggad	cat o	catt	tttc	cc aa	aaagt	ctto	g gaa	aatga	acag	gaaa	atatt	iga t	gaag	gcagaa	1	.620
tggg	gagto	gga a	aagca	aggat	t co	catco	gatgo	g aac	caatt	aca	tgat	gga	ctg (gaaaa	aatcaa	1	.680
ttta	aacga	att a	acact	agca	aa ga	aaaga	aaagt	tgt:	gtgg	ggtc	tc					1	722
<211 <212 <213 <220 <223	<pre><210> SEQ ID NO 2 <211> LENGTH: 574 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) aminio acid</pre>																
	Clu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met																
GIu 1	Asp	Asp	Ile	Ile 5	Ile	Ala	Thr	ГЛЗ	Asn 10	GIY	ГÀЗ	Val	Arg	G1y 15	Met		
Asn	Leu	Thr	Val 20	Phe	Gly	Gly	Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro		
Tyr	Ala	Gln 35	Pro	Pro	Leu	Gly	Arg 40	Leu	Arg	Phe	ГÀв	Lys 45	Pro	Gln	Ser		
Leu	Thr 50	Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	Lys	Tyr	Ala	Asn	Ser		
Сув 65	Cys	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80		
Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	CÀa	Leu	Tyr	Leu 95	Asn		
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp		
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr		
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met		
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160		
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln		
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val		
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu		
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser		
Gly 225	Ser	Phe	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240		
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	Cys	Ser	Arg	Glu 255	Asn		
Glu	Thr	Glu	Ile 260	Ile	Lys	Cys	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile		
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Ser	Val		
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp		
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320		
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly		

Phe	Ser	ГÀа	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu		
Gly	Leu	Lys 355		Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser		
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn		
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400		
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala		
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu		
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu		
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser		
Arg 465	Ser	Ile	Val	ГЛа	Arg 470	Trp	Ala	Asn	Phe	Ala 475	ГЛа	Tyr	Gly	Asn	Pro 480		
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr		
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr		
ГЛа	Leu	Arg 515	Ala	Gln	Gln	СЛа	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys		
Val	Leu 530	Glu	Met	Thr	Gly	Asn 535	Ile	Asp	Glu	Ala	Glu 540	Trp	Glu	Trp	ГЛа		
Ala 545	Gly	Phe	His	Arg	Trp 550	Asn	Asn	Tyr	Met	Met 555	Asp	Trp	Lys	Asn	Gln 560		
Phe	Asn	Asp	Tyr	Thr 565	Ser	Lys	Lys	Glu	Ser 570	Càa	Val	Gly	Leu				
<213 <213 <213 <220 <223		ENGTH PE: RGANI EATUR THER equer	H: 11 DNA ISM: RE: INFO	Arti Arti ORMAT	: NOI	tru									nucleid Nues 68		
aaca	ataga	atc a	aaagt	ttt	cc aç	ggctt	ccat	gga	atcaç	gaga	tgt	ggaa	ccc a	aaaca	actgac		60
ctca	agtga	aag a	actg	ttat	a to	ctaaa	atgta	a tgg	gatto	ccag	caco	ctaaa	acc a	aaaa	aatgcc	1	.20
acto	gtatt	ga t	tatg	gatti	a to	ggtgg	gtggt	ttt	caaa	actg	gaad	catca	atc 1	tttad	catgtt	1	.80
tate	gatgo	gca a	agtti	ctg	gc to	gggt	tgaa	a aga	agtta	attg	tagt	gtca	aat 🤄	gaact	atagg	2	40
gtg	ggtgo	ccc t	tagga	attct	t aç	gettt	gcca	a gga	aaato	cctg	agg	ctcca	agg (gaaca	atgggt	3	00
ttat	ttga	atc a	aaca	gttg	gc to	ettea	agtgg	ggtt	caaa	aaaa	atai	cagca	agc (cttt	ggtgga	3	60
aato	cctaa	aaa q	gtgta	aacto	et et	ttg	gagaa	a agt	teeç	ggag	cago	cttca	agt t	tage	ctgcat	4	20
ttg	ettte	ete d	ctgga	aagco	ca t	catt	gtto	c acc	cagaç	gcca	ttc	gcaa	aag t	tggti	ccttt	4	80
aat	getec	ett (gggc	ggtaa	ac at	ctct	ttat	gaa	agcta	agga	acaç	gaac	gtt (gaact	tagct	5	40
aaat	tgad	ctg q	gttg	ctcta	ag aç	gagaa	atgag	g act	gaaa	ataa	tcaa	agtgt	ct 1	tagaa	aataaa	6	00
gato	ccca	aag a	aaati	ctt	et ga	aatga	aagca	a ttt	gtt	gtcc	ccta	atgg	gac t	tccti	tgtca	6	60

-continued
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 720
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 780
tggtttttag teggtggtge teetggette agcaaagata acaatagtat cataactaga 840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 1020
aagttotoag aatggggaaa taatgoottt ttotactatt ttgaacaccg atootocaaa 1080
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 1125
<210> SEQ ID NO 4 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: truncated 14-1 mutant (A199S/A328/Y332G) amino acid sequence of modified BChE <400> SEQUENCE: 4
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn
1 5 10 15
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 20 25 30
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 35 40 45
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 50 55 60
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 65 70 75 80
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 85 90 95
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 100 105 110
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe 115 120 125
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 130 135 140
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe 145 150 155 160
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 165 170 175
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 180 185 190
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 195 200 205
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly 210 215 220
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 225 230 235 240
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 245 250 255
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys 260 265 270
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys

-continued

```
285
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe
                        295
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu
305
                   310
                                        315
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu
                                    330
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly
Val Met His Gly Tyr Glu Ile
   370
<210> SEQ ID NO 5
<211> LENGTH: 966
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE nucleic
     acid sequnce corresponding to a.a. residues 117-438
<400> SEQUENCE: 5
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag
                                                                     180
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga
                                                                     240
qaaaqttccq qaqcaqcttc aqttaqcctq catttqcttt ctcctqqaaq ccattcattq
                                                                     300
ttcaccagag ccattctgca aagtggttcc tttaatgctc cttgggcggt aacatctctt
                                                                     360
tatgaaqcta ggaacaqaac gttgaactta gctaaattga ctggttgctc tagaqagaat
                                                                     420
qaqactqaaa taatcaaqtq tcttaqaaat aaaqatcccc aaqaaattct tctqaatqaa
                                                                     480
gcatttgttg tcccctatgg gactcctttg tcagtaaact ttggtccgac cgtggatggt
                                                                     540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag
                                                                      600
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc
                                                                      660
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaaata
                                                                      720
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg
                                                                      780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat
                                                                      840
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc
                                                                      900
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg
                                                                      960
atgcat
                                                                      966
<210> SEQ ID NO 6
<211> LENGTH: 322
<212> TYPE: PRT
<213> ORGANISM: Artificial
<223> OTHER INFORMATION: 14-1 mutant (A199S/A328W/Y332G) BChE a.a.
     residues 117-438
<400> SEQUENCE: 6
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe
```

10

												COII	C 111	aca		
Leu	Ala	Arg	Val 20	Glu	Arg	Val	Ile	Val 25	Val	Ser	Met	Asn	Tyr 30	Arg	Val	
Gly	Ala	Leu 35	Gly	Phe	Leu	Ala	Leu 40	Pro	Gly	Asn	Pro	Glu 45	Ala	Pro	Gly	
Asn	Met 50	Gly	Leu	Phe	Asp	Gln 55	Gln	Leu	Ala	Leu	Gln 60	Trp	Val	Gln	Lys	
Asn 65	Ile	Ala	Ala	Phe	Gly 70	Gly	Asn	Pro	Lys	Ser 75	Val	Thr	Leu	Phe	Gly 80	
Glu	Ser	Ser	Gly	Ala 85	Ala	Ser	Val	Ser	Leu 90	His	Leu	Leu	Ser	Pro 95	Gly	
Ser	His	Ser	Leu 100	Phe	Thr	Arg	Ala	Ile 105	Leu	Gln	Ser	Gly	Ser 110	Phe	Asn	
Ala	Pro	Trp 115	Ala	Val	Thr	Ser	Leu 120	Tyr	Glu	Ala	Arg	Asn 125	Arg	Thr	Leu	
Asn	Leu 130	Ala	Lys	Leu	Thr	Gly 135	Сла	Ser	Arg	Glu	Asn 140	Glu	Thr	Glu	Ile	
Ile 145	Lys	Сув	Leu	Arg	Asn 150	Lys	Asp	Pro	Gln	Glu 155	Ile	Leu	Leu	Asn	Glu 160	
Ala	Phe	Val	Val	Pro 165	Tyr	Gly	Thr	Pro	Leu 170	Ser	Val	Asn	Phe	Gly 175	Pro	
Thr	Val	Asp	Gly 180	Asp	Phe	Leu	Thr	Asp 185	Met	Pro	Asp	Ile	Leu 190	Leu	Glu	
Leu	Gly	Gln 195	Phe	ГÀа	ГÀа	Thr	Gln 200	Ile	Leu	Val	Gly	Val 205	Asn	Lys	Asp	
Glu	Gly 210	Thr	Trp	Phe	Leu	Val 215	Gly	Gly	Ala	Pro	Gly 220	Phe	Ser	Lys	Asp	
Asn 225	Asn	Ser	Ile	Ile	Thr 230	Arg	ГÀа	Glu	Phe	Gln 235	Glu	Gly	Leu	Lys	Ile 240	
Phe	Phe	Pro	Gly	Val 245	Ser	Glu	Phe	Gly	Lys 250	Glu	Ser	Ile	Leu	Phe 255	His	
Tyr	Thr	Asp	Trp 260	Val	Asp	Asp	Gln	Arg 265	Pro	Glu	Asn	Tyr	Arg 270	Glu	Ala	
Leu	Gly	Asp 275	Val	Val	Gly	Asp	Tyr 280	Asn	Phe	Ile	CAa	Pro 285	Ala	Leu	Glu	
Phe	Thr 290	Lys	Lys	Phe	Ser	Glu 295	Trp	Gly	Asn	Asn	Ala 300	Phe	Phe	Tyr	Tyr	
Phe 305	Glu	His	Arg	Ser	Ser 310	Lys	Leu	Pro	Trp	Pro 315	Glu	Trp	Met	Gly	Val 320	
Met	His															
<210)> SE	0 II	NO NO	7												
<211	.> LE	ENGTH	H: 17													
		PE : RGANI		Arti	lfici	al										
		EATUF				- 4			. /3.4	000	/=	73 /34		/*** > 0	a) Dal-E	
<223				eic a					(A)	.998,	F22	/A/A:	328W,	Y332	RG) BChE,	
		-	ICE:		gc aa	acaa	agaat	gaa	aaaa	gtca	gaq	ggato	gaa (etta	acagtt	60
	_						-						_	_	ggtaga	120
		_			=					_		_			acaaaa	180
tato	jcaaa	att (ettge	ctgt	ca ga	aacat	tagat	caa	aagtt	ttc	cag	gctt	cca 1	ggat	cagag	240
atgt	ggaa	acc o	caaa	cact	ga co	ctca	gtgaa	a gad	ctgtt	tat	atc	caaat	tgt a	atgga	attcca	300

-continued

```
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact
                                                                     360
qqaacatcat ctttacatqt ttatqatqqc aaqtttctqq ctcqqqttqa aaqaqttatt
                                                                     420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct
                                                                     480
gaggetecag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa
                                                                     540
aatataqcaq cctttqqtqq aaatcctaaa aqtqtaactc tctttqqaqa aaqttccqqa
                                                                     600
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc
                                                                     660
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg
                                                                     720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata
                                                                     780
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc
                                                                     840
ccctatggga ctcctttgtc agtaaacttt ggtccgaccg tggatggtga ttttctcact
                                                                     900
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt
                                                                     960
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat
                                                                    1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaaatatt ttttccagga
                                                                    1080
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc
                                                                    1200
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat
qaaattqaat ttqtctttqq tttacctctq qaaaqaaqaq ataattacac aaaaqccqaq
                                                                    1380
qaaattttga qtaqatccat aqtqaaacqq tqqqcaaatt ttqcaaaata tqqqaatcca
                                                                    1440
aatqaqactc aqaacaataq cacaaqctqq cctqtcttca aaaqcactqa acaaaaatat
                                                                    1500
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga
                                                                    1560
ttctggacat catttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa
                                                                    1620
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa
                                                                    1680
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc
                                                                    1722
<210> SEQ ID NO 8
<211> LENGTH: 574
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G), full
     nucleic acid sequence
<400> SEQUENCE: 8
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn
```

Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp

_			100					105					110		
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lуs 190	Ser	Val
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	CAa	Ser	Arg	Glu 255	Asn
Glu	Thr	Glu	Ile 260	Ile	ГÀа	CÀa	Leu	Arg 265	Asn	ГÀа	Asp	Pro	Gln 270	Glu	Ile
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Ser	Val
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	Lys	Lys	Thr 315	Gln	Ile	Leu	Val	Gly 320
Val	Asn	ГÀа	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	ГÀа	Glu	Phe 350	Gln	Glu
Gly	Leu	355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	400 Cys
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	ГÀЗ	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	ГÀз	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn 485	Asn	Ser	Thr	Ser	Trp 490	Pro	Val	Phe	Lys	Ser 495	Thr
Glu	Gln	Lys	Tyr 500	Leu	Thr	Leu	Asn	Thr 505	Glu	Ser	Thr	Arg	Ile 510	Met	Thr
ГÀа	Leu	Arg 515	Ala	Gln	Gln	Cys	Arg 520	Phe	Trp	Thr	Ser	Phe 525	Phe	Pro	Lys

```
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys
                        535
   530
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln
                                        555
                    550
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu
                565
<210> SEQ ID NO 9
<211> LENGTH: 1125
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-2 mutant (A199/F227A/A328W/Y322G) BChE
     nucleic acid sequence for a.a. residues 68-442
<400> SEQUENCE: 9
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac
                                                                      60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct
                                                                     480
aatgeteett gggeggtaac atetetttat gaagetagga acagaacgtt gaacttaget
                                                                     540
aaattqactq qttqctctaq aqaqaatqaq actqaaataa tcaaqtqtct taqaaataaa
                                                                     600
gatececaag aaattettet gaatgaagea titigtigtee eetatgggae teetitigtea
                                                                     660
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt
                                                                     720
                                                                     780
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga
                                                                     840
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa
                                                                     900
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag
                                                                     960
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag
                                                                    1020
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa
                                                                    1080
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt
                                                                    1125
<210> SEQ ID NO 10
<211> LENGTH: 375
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-2 mutant (A199S/F227A/A328W/Y332G) BChE,
     amino acid sequence for residues 68-442
<400> SEQUENCE: 10
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn
                                    10
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly
```

Gly Gly Phe Gln Thr Gly Thr 50 55	Ger Ser Leu His Val Tyr Asp G 60	Gly Lys
Phe Leu Ala Arg Val Glu Arg	<i>y</i> al Ile Val Val Ser Met Asn T 75	Tyr Arg 80
Val Gly Ala Leu Gly Phe Leu . 85	Ala Leu Pro Gly Asn Pro Glu A 90	Ala Pro 95
Gly Asn Met Gly Leu Phe Asp	Gln Gln Leu Ala Leu Gln Trp V 105 110	Val Gln
= = = = = = = = = = = = = = = = = = = =	Gly Asn Pro Lys Ser Val Thr L 120 125	ueu Phe
Gly Glu Ser Ser Gly Ala Ala 130 135	Ser Val Ser Leu His Leu Leu S 140	Ger Pro
Gly Ser His Ser Leu Phe Thr . 145 150	Arg Ala Ile Leu Gln Ser Gly S 155	Ser Ala 160
Asn Ala Pro Trp Ala Val Thr	Ger Leu Tyr Glu Ala Arg Asn A 170 1	Arg Thr 175
Leu Asn Leu Ala Lys Leu Thr	Gly Cys Ser Arg Glu Asn Glu T 185 190	Thr Glu
	Lys Asp Pro Gln Glu Ile Leu L 200 205	Leu Asn
Glu Ala Phe Val Val Pro Tyr 210 215	Gly Thr Pro Leu Ser Val Asn F 220	Phe Gly
Pro Thr Val Asp Gly Asp Phe 225 230	Leu Thr Asp Met Pro Asp Ile L 235	Leu Leu 240
Glu Leu Gly Gln Phe Lys Lys 245	Thr Gln Ile Leu Val Gly Val A 250 2	Asn Lys 255
Asp Glu Gly Thr Trp Phe Leu 260	Val Gly Gly Ala Pro Gly Phe S 265 270	Ser Lys
	Arg Lys Glu Phe Gln Glu Gly L 280 285	eu Lys
Ile Phe Phe Pro Gly Val Ser 290 295	Glu Phe Gly Lys Glu Ser Ile I 300	ueu Phe
His Tyr Thr Asp Trp Val Asp . 305 310	Asp Gln Arg Pro Glu Asn Tyr A 315	Arg Glu 320
Ala Leu Gly Asp Val Val Gly . 325		Ala Leu 35
Glu Phe Thr Lys Lys Phe Ser	Glu Trp Gly Asn Asn Ala Phe F 345 350	Phe Tyr
	Lys Leu Pro Trp Pro Glu Trp M 360 365	Met Gly
Val Met His Gly Tyr Glu Ile 370 375		
<210> SEQ ID NO 11 <211> LENGTH: 966 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 amino acid sequence fo	nutant (A199S/F227A/A328W/Y residues 117-438	7332G) BChE
<400> SEQUENCE: 11		
ggttttcaaa ctggaacatc atcttt	acat gtttatgatg gcaagtttct gg	getegggtt 60
gaaagagtta ttgtagtgtc aatgaa	ctat agggtgggtg ccctaggatt ct	tagctttg 120
ccaggaaatc ctgaggctcc agggaa	catg ggtttatttg atcaacagtt gg	getetteag 180

tgggttcaaa aaaatatagc agcetttggt ggaaateeta aaagtgtaae tetetttgga	240
gaaagtteeg gageagette agttageetg eatttgettt eteetggaag eeatteattg	300
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggt aacatctctt	360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat	420
gagactgaaa taatcaagtg tottagaaat aaagatooco aagaaattot totgaatgaa	480
gcatttgttg teceetatgg gaeteetttg teagtaaact ttggteegae egtggatggt	540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag	600
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc	660
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata	720
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg	780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat	840
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc	900
ttttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg	960
atgcat	966
<pre><210> SEQ ID NO 12 <211> LENGTH: 322 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-2 (A199S/F227A/A328W/Y332G) a.a residues</pre>	
<400> SEQUENCE: 12	
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 1 5 10 15	
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 20 25 30	
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 35 40 45	
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 50 60	
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 65 70 75 80	
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 85 90 95	
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 100 105 110	
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 115 120 125	
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 130 135 140	
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 145 150 155 160	
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly Pro	
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 180 185 190	
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp	
195 200 205	

Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 210 215 220
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 225 230 235 240
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 245 250 255
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 260 265 270
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 275 280 285
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 290 295 300
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val
305 310 315 320 Met His
<pre><210> SEQ ID NO 13 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE nucleic acid sequence <400> SEQUENCE: 13</pre>
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 180
tatqcaaatt cttqctqtca qaacataqat caaaqttttc caqqcttcca tqqatcaqaq 240
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 480
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 540
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 600
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 660
attetgeaaa gtggtteett taatgeteet tgggeggtaa eatetettta tgaagetagg 720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 900
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 960
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 1080
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 1260
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 1380

gaaatti	tga	gtag	atcca	at a	gtgaa	aacg	g tgg	ggcaa	aatt	ttg	caaa	ata 1	tggga	aatcca	1440
aatgaga	actc	agaa	caat	ag ca	acaa	gctg	g cct	gtct	ttca	aaa	gcact	tga a	acaaa	aaatat	1500
ctaacct	tga	atac	agagi	tc a	acaa	gaata	a ato	gacga	aaac	tac	gtgc	tca a	acaat	tgtcga	1560
ttctgga	acat	catt	tttt	cc a	aaagi	tcttç	g gaa	aatga	acag	gaa	atati	tga 1	tgaaq	gcagaa	1620
tgggagt	gga	aagc	agga	tt c	catc	gctg	gaad	caatt	taca	tga	tgga	ctg (gaaa	aatcaa	1680
tttaaco	gatt	acac	tagc	aa ga	aaaga	aaagt	tgt	gtg	ggtc	tc					1722
	ENGT TYPE: PRGAN EATU THER amino	H: 5' PRT ISM: RE: INF(aci	74 Art: ORMA: d sec	rion:	: 14-	-3 mu	ıtant	: (A1	L99S/	[/] S28 ⁻	7G/A3	328W/	/Y332	2G) BChE	:
Glu Asp				Ile	Ala	Thr	Lys	Asn	Gly	Lys	Val	Arg	Gly 15	Met	
Asn Let	ı Thr	Val	Phe	Gly	Gly	Thr	Val 25		Ala	Phe	Leu	Gly 30		Pro	
Tyr Ala	a Gln 35		Pro	Leu	Gly	Arg 40		Arg	Phe	Lys	Lys 45		Gln	Ser	
Leu Thi	. Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	Lys	Tyr	Ala	Asn	Ser	
Cys Cys	s Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80	
Met Tr) Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	СЛа	Leu	Tyr	Leu 95	Asn	
Val Tr	lle	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp	
Ile Ty	Gly 115		Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr	
Asp Gly	_	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met	
Asn Tyr 145	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160	
Glu Ala	a Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln	
Trp Val	l Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lув 190	Ser	Val	
Thr Let	195	•				200					205				
Leu Ser 210)	•			215				J	220					
Gly Ser 225				230	_				235		-			240	
Asn Arç			245			-		250	-	-		_	255		
Glu Th		260		-	-		265		-	_		270			
Leu Le	1 Asn 275		Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val	
Asn Phe	e Gly	Pro	Thr	Val	Asp	Gly	Asp	Phe	Leu	Thr	Asp	Met	Pro	Asp	

-continued

Concinaca
290 295 300
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 305 310 315 320
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 325 330 335
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu 340 345 350
Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser 355 360 365
Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn 370 375 380
Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 385 390 395 400
Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 405 410 415
Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 420 425 430
Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu 435 440 445
Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 450 455 460
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 465 470 475 480
Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 485 490 495
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 505 510
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 520 525
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 535 540
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 550 555 560
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570
<pre><210> SEQ ID NO 15 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 15</pre>
aacataqatc aaaqttttcc aqqcttccat qqatcaqaqa tqtqqaaccc aaacactqac 60
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360
aatootaaaa gtgtaactot otttggagaa agttooggag cagottoagt tagootgoat 420

ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccttt

aatgetee	tt gggc	ggtaa	c atct	cttta	t gaa	agcta	ıgga	acaç	gaac	gtt (gaact	taget	540
aaattgac	tg gttg	ctctaç	g agag	aatga	g act	tgaaa	taa	tcaa	agtg	ct 1	tagaa	aataaa	600
gatcccca	ag aaat	tcttct	t gaat	gaagc	a tti	tgttç	gtcc	ccta	atgg	gac 1	tcctt	tgggt	660
gtaaactt	tg gtcc	gaccgt	t ggat	ggtga	t tti	tctca	ctg	acat	gcc	aga (catat	tactt	720
gaacttgg	ac aatt	taaaaa	a aacc	cagat	t tt	ggtgg	gtg	ttaa	ataa	aga 1	tgaag	gggaca	780
tggttttt	ag tegg	tggtg	c tect	ggctt	c ago	caaaç	gata	acaa	atagi	tat (cataa	actaga	840
aaagaatt	tc agga	aggtti	t aaaa	atatt	t tti	tccaç	gag	tgaç	gtga	gtt 1	tggaa	aaggaa	900
tccatcct	tt ttca	ttacad	c agac	tgggt.	a gat	tgato	aga	gaco	ctga	aaa (ctaco	cgtgag	960
gccttggg	tg atgt	tgttg	g ggat	tataa	t tt	catat	gcc	ctg	cctt	gga g	gttca	accaag	1020
aagttctc	ag aatg	gggaaa	a taat	gcctt	t tt	ctact	att	ttga	aaca	ccg a	atcct	ccaaa	1080
cttccgtg	gc caga	atggat	t ggga	gtgat	g cat	tggct	atg	aaat	t				1125
	NGTH: 3 PE: PRT GANISM: ATURE: HER INF ino aci	75 Artif ORMATI d sequ	ION: 1						'G/A3	328W/	/Y332	2G) BChE	:
<400> SE							417	_			_	_	
Asn Ile . 1	Asp Gln	Ser 1 5	Phe Pr	o GIY	Phe	His 10	GIY	Ser	GIu	Met	Trp 15	Asn	
Pro Asn	Thr Asp 20	Leu S	Ser Gl	u Asp	Cys 25	Leu	Tyr	Leu	Asn	Val 30	Trp	Ile	
Pro Ala	Pro Lys 35	Pro I	Lys As	n Ala 40	Thr	Val	Leu	Ile	Trp 45	Ile	Tyr	Gly	
Gly Gly 50	Phe Gln	Thr (Gly Th 55	r Ser	Ser	Leu	His	Val 60	Tyr	Asp	Gly	Lys	
Phe Leu . 65	Ala Arg		Glu Ar 70	g Val	Ile	Val	Val 75	Ser	Met	Asn	Tyr	Arg 80	
Val Gly	Ala Leu	Gly I 85	Phe Le	u Ala	Leu	Pro 90	Gly	Asn	Pro	Glu	Ala 95	Pro	
Gly Asn	Met Gly 100		Phe As	p Gln	Gln 105	Leu	Ala	Leu	Gln	Trp 110	Val	Gln	
Lys Asn	Ile Ala 115	Ala I	Phe Gl	y Gly 120		Pro	Lys	Ser	Val 125	Thr	Leu	Phe	
Gly Glu 130	Ser Ser	Gly A	Ala Al 13		Val	Ser	Leu	His 140	Leu	Leu	Ser	Pro	
Gly Ser	His Ser		Phe Th 150	r Arg	Ala	Ile	Leu 155	Gln	Ser	Gly	Ser	Phe 160	
Asn Ala	Pro Trp	Ala V 165	Val Th	r Ser	Leu	Tyr 170	Glu	Ala	Arg	Asn	Arg 175	Thr	
Leu Asn	Leu Ala 180		Leu Th	r Gly	Суs 185	Ser	Arg	Glu	Asn	Glu 190	Thr	Glu	
Ile Ile	Lys Cys 195	Leu A	Arg As	n Lys 200	Asp	Pro	Gln	Glu	Ile 205	Leu	Leu	Asn	
Glu Ala 210	Phe Val	Val I	Pro Ty 21		Thr	Pro	Leu	Gly 220	Val	Asn	Phe	Gly	
Pro Thr	Val Asp		Asp Ph 230	e Leu	Thr	Asp	Met 235	Pro	Asp	Ile	Leu	Leu 240	

```
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys
                245
                                    250
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys
           260
                                265
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys
                            280
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe
                        295
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu
                   310
                                       315
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu
               325
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly
                            360
Val Met His Gly Tyr Glu Ile
   370
<210> SEQ ID NO 17
<211> LENGTH: 966
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE
     nucleic acid sequence for amino acid residues 117-438
<400> SEQUENCE: 17
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt
                                                                      60
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg
                                                                     120
ccaqqaaatc ctqaqqctcc aqqqaacatq qqtttatttq atcaacaqtt qqctcttcaq
                                                                     180
tqqqttcaaa aaaatataqc aqcctttqqt qqaaatccta aaaqtqtaac tctctttqqa
                                                                     240
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg
                                                                     300
ttcaccagag ccattctgca aagtggttcc tttaatgctc cttgggcggt aacatctctt
                                                                     360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat
                                                                     420
gagactgaaa taatcaagtg tottagaaat aaagatooco aagaaattot totgaatgaa
                                                                     480
gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt
                                                                     540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag
                                                                     600
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc
                                                                     660
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaaata
                                                                     720
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg
                                                                     780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat
                                                                     840
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg
atgcat
                                                                     966
<210> SEQ ID NO 18
<211> LENGTH: 322
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 14-3 mutant (A199S/S287G/A328W/Y332G) BChE
```

```
amino acid sequence for residues 117-438
<400> SEOUENCE: 18
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe
                      10
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val
                             25
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu
                120
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu
                   185
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp
                 200
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp
                      215
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile
                  230
                                      235
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His
                               250
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala
                             265
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr
              295
                                  300
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val
Met His
<210> SEQ ID NO 19
<211> LENGTH: 1722
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)
     BChE nucleic acid sequence
<400> SEQUENCE: 19
```

-continued

```
tttqqtqqca cqqtaacaqc ctttcttqqa attccctatq cacaqccacc tcttqqtaqa
                                                                     120
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa
                                                                     180
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag
                                                                     240
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca
                                                                     300
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact
                                                                     360
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt
                                                                     420
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct
                                                                     480
gaggetecag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa
                                                                     540
aatatagcag cetttggtgg aaateetaaa agtgtaacte tetttggaga aagtteegga
                                                                     600
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc
                                                                     660
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg
                                                                     720
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata
                                                                     780
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc
                                                                     840
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact
                                                                     900
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt
                                                                     960
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat
                                                                    1020
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga
                                                                    1080
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag
                                                                    1140
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc
                                                                    1200
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat
                                                                    1260
                                                                    1320
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat
qaaattqaat ttqtctttqq tttacctctq qaaaqaaqaq ataattacac aaaaqccqaq
                                                                    1380
qaaattttqa qtaqatccat aqtqaaacqq tqqqcaaatt ttqcaaaata tqqqaatcca
                                                                    1440
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat
                                                                    1500
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga
                                                                    1560
ttctggacat catttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa
                                                                    1620
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa
                                                                    1680
                                                                    1722
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc
```

```
<210> SEQ ID NO 20
```

<400> SEQUENCE: 20

Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 1 $$ 10 $$ 15

Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro

Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 35 40 45

Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 50 60

<211> LENGTH: 574

<211> LENGTH: 57-

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence

												0011	CIII	aca	
65 CAa	Cha	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80
Met	Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	Cys	Leu	Tyr	Leu 95	Asn
Val	Trp	Ile	Pro 100	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp
Ile	Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr
Asp	Gly 130	Lys	Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met
Asn 145	Tyr	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160
Glu	Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln
Trp	Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val
Thr	Leu	Phe 195	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu
Leu	Ser 210	Pro	Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser
Gly 225	Ser	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240
Asn	Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	CÀa	Ser	Arg	Glu 255	Asn
Glu	Thr	Glu	Ile 260	Ile	Lys	Cys	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile
Leu	Leu	Asn 275	Glu	Ala	Phe	Val	Val 280	Pro	Tyr	Gly	Thr	Pro 285	Leu	Gly	Val
Asn	Phe 290	Gly	Pro	Thr	Val	Asp 295	Gly	Asp	Phe	Leu	Thr 300	Asp	Met	Pro	Asp
Ile 305	Leu	Leu	Glu	Leu	Gly 310	Gln	Phe	ГЛа	ГЛа	Thr 315	Gln	Ile	Leu	Val	Gly 320
Val	Asn	Lys	Asp	Glu 325	Gly	Thr	Trp	Phe	Leu 330	Val	Gly	Gly	Ala	Pro 335	Gly
Phe	Ser	Lys	Asp 340	Asn	Asn	Ser	Ile	Ile 345	Thr	Arg	Lys	Glu	Phe 350	Gln	Glu
Gly	Leu	Lys 355	Ile	Phe	Phe	Pro	Gly 360	Val	Ser	Glu	Phe	Gly 365	Lys	Glu	Ser
Ile	Leu 370	Phe	His	Tyr	Thr	Asp 375	Trp	Val	Asp	Asp	Gln 380	Arg	Pro	Glu	Asn
Tyr 385	Arg	Glu	Ala	Leu	Gly 390	Asp	Val	Val	Gly	Asp 395	Tyr	Asn	Phe	Ile	Cys 400
Pro	Ala	Leu	Glu	Phe 405	Thr	Lys	Lys	Phe	Ser 410	Glu	Trp	Gly	Asn	Asn 415	Ala
Phe	Phe	Tyr	Tyr 420	Phe	Glu	His	Arg	Ser 425	Ser	Lys	Leu	Pro	Trp 430	Pro	Glu
Trp	Met	Gly 435	Val	Met	His	Gly	Tyr 440	Glu	Ile	Glu	Phe	Val 445	Phe	Gly	Leu
Pro	Leu 450	Glu	Arg	Arg	Asp	Asn 455	Tyr	Thr	Lys	Ala	Glu 460	Glu	Ile	Leu	Ser
Arg 465	Ser	Ile	Val	Lys	Arg 470	Trp	Ala	Asn	Phe	Ala 475	Lys	Tyr	Gly	Asn	Pro 480
Asn	Glu	Thr	Gln	Asn	Asn	Ser	Thr	Ser	Trp	Pro	Val	Phe	Lys	Ser	Thr

-continued

485 490 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 505 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 520 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 535 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 <210> SEQ ID NO 21 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 21 aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 240 tatqatqqca aqtttctqqc tcqqqttqaa aqaqttattq taqtqtcaat qaactataqq gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300 ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360 aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 420 ttqctttctc ctqqaaqcca ttcattqttc accaqaqcca ttctqcaaaq tqqttccqct 480 aatqctcctt qqqcqqtaac atctctttat qaaqctaqqa acaqaacqtt qaacttaqct 540 aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 600 qatccccaaq aaattcttct qaatqaaqca tttqttqtcc cctatqqqac tcctttqqqt 660 gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 720 gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 780 tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 840 aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 900 tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 960 gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 1020 aagttotoag aatggggaaa taatgoottt ttotactatt ttgaacaccg atcotocaaa 1080 cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 1125 <210> SEQ ID NO 22 <211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 68-442

Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 10

-continued

Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 40 Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 55 Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 90 Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 105 Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly 210 215 Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 235 230 Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 245 250 Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys 265 Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys 280 Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 295 His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 325 330 Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 345 Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 355 360 Val Met His Gly Tyr Glu Ile <210> SEQ ID NO 23 <211> LENGTH: 966 <212> TYPE: DNA <213> ORGANISM: Artificial <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE nucleic acid sequence for amino acid residues 117-438

<400> SEQUENCE: 23	
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt	60
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg	120
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag	180
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga	240
gaaagtteeg gageagette agttageetg catttgettt eteetggaag ceatteattg	300
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggt aacatctctt	360
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat	420
gagactgaaa taatcaagtg tottagaaat aaagatooco aagaaattot totgaatgaa	480
gcatttgttg teceetatgg gaeteetttg ggtgtaaaet ttggteegae egtggatggt	540
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag	600
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc	660
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata	720
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg	780
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat	840
aattteatat geeetgeett ggagtteace aagaagttet eagaatgggg aaataatgee	900
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg	960
atgcat	966
<211> LENGTH: 322 <212> TYPE: PRT	
<pre><21> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)	
<213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A1995/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438 <400> SEQUENCE: 24 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G)</pre>	
<pre><213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) BChE amino acid sequence for residues 117-438 <400> SEQUENCE: 24 Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 1</pre>	

-continued

Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 185 Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 200 Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 215 Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 230 Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 250 Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 310 315 Met His <210> SEQ ID NO 25 <211> LENGTH: 1722 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChe nucleic acid sequence <400> SEQUENCE: 25 gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60 tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120 cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 180 tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 240 atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 300 gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360 ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 420 gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 480 gaggetecag ggaacatggg tttatttgat caacagttgg etetteagtg ggtteaaaaa 540 aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 600 gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 660 attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg 720 780 aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840 ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt gttaataaag atgaagggac atggttttta gtctatggtg ctcctggctt cagcaaagat aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga qtqaqtqaqt ttqqaaaqqa atccatcctt tttcattaca caqactqqqt aqatqatcaq 1140

										-	con	tin	ued		
agacctg	aaa .	acta	ccgt	ga gg	gcctt	tgggt	gat	tgttg	gttg	999	attat	caa	tttca	atatgc	1200
cctgcct	tgg (agtto	cacca	aa ga	aagtt	tctca	a gaa	atgg	ggaa	ataa	atgc	ett	tttct	tactat	1260
tttgaac	acc (gatco	ctcca	aa a	cttco	egtg	g cca	agaat	gga	tgg	gagt	gat (gcato	ggctat	1320
gacattg	aat 1	ttgt	cttt	gg tt	taco	ctctç	g gaa	aagaa	agag	ataa	attad	cac .	aaaa	gccgag	1380
gaaattt	tga 🤉	gtaga	atcca	at aç	gtgaa	aacgg	g tg	ggcaa	aatt	ttg	caaaa	ata	tggga	aatcca	1440
aatgaga	ctc	agaa	caata	ag ca	acaaç	gatgo	g cct	tgtct	tca	aaaq	gcact	ga .	acaa	aaatat	1500
ctaacct	tga .	ataca	agagt	c aa	acaa	gaata	a ato	gacga	aaac	tac	gtgct	ca .	acaat	gtcga	1560
ttctgga	cat (catti	ttt	cc aa	aaagt	tatte	g gaa	aatga	acag	gaaa	atati	ga	tgaaq	gcagaa	1620
tgggagt	gga i	aagca	aggat	t co	catco	gatgo	g aad	caatt	caca	tgat	gga	ctg	gaaaa	aatcaa	1680
tttaacg	att 4	acact	cagca	aa ga	aaaga	aaagt	t tgt	tgtg	ggtc	tc					1722
	ENGTI YPE : RGAN: EATUI	H: 57 PRT ISM: RE: INFO	74 Arti ORMAT	: NOI	12-		ıtant	: (A1	.99S/	[/] F227	7A/S2	287G,	/A328	3W/E441D)
<400> S	EQUEI	ICE :	26												
Glu Asp 1	Asp	Ile	Ile 5	Ile	Ala	Thr	Lys	Asn 10	Gly	rys	Val	Arg	Gly 15	Met	
Asn Leu	Thr	Val 20	Phe	Gly	Gly	Thr	Val 25	Thr	Ala	Phe	Leu	Gly 30	Ile	Pro	
Tyr Ala	Gln 35	Pro	Pro	Leu	Gly	Arg 40	Leu	Arg	Phe	Lys	Lys 45	Pro	Gln	Ser	
Leu Thr 50	Lys	Trp	Ser	Asp	Ile 55	Trp	Asn	Ala	Thr	60 Fåa	Tyr	Ala	Asn	Ser	
Cys Cys 65	Gln	Asn	Ile	Asp 70	Gln	Ser	Phe	Pro	Gly 75	Phe	His	Gly	Ser	Glu 80	
Met Trp	Asn	Pro	Asn 85	Thr	Asp	Leu	Ser	Glu 90	Asp	Cys	Leu	Tyr	Leu 95	Asn	
Val Trp	Ile	Pro	Ala	Pro	Lys	Pro	Lys 105	Asn	Ala	Thr	Val	Leu 110	Ile	Trp	
Ile Tyr	Gly 115	Gly	Gly	Phe	Gln	Thr 120	Gly	Thr	Ser	Ser	Leu 125	His	Val	Tyr	
Asp Gly		Phe	Leu	Ala	Arg 135	Val	Glu	Arg	Val	Ile 140	Val	Val	Ser	Met	
Asn Tyr 145	Arg	Val	Gly	Ala 150	Leu	Gly	Phe	Leu	Ala 155	Leu	Pro	Gly	Asn	Pro 160	
Glu Ala	Pro	Gly	Asn 165	Met	Gly	Leu	Phe	Asp 170	Gln	Gln	Leu	Ala	Leu 175	Gln	
Trp Val	Gln	Lys 180	Asn	Ile	Ala	Ala	Phe 185	Gly	Gly	Asn	Pro	Lys 190	Ser	Val	
Thr Leu	Phe	Gly	Glu	Ser	Ser	Gly 200	Ala	Ala	Ser	Val	Ser 205	Leu	His	Leu	
Leu Ser 210		Gly	Ser	His	Ser 215	Leu	Phe	Thr	Arg	Ala 220	Ile	Leu	Gln	Ser	
Gly Ser 225	Ala	Asn	Ala	Pro 230	Trp	Ala	Val	Thr	Ser 235	Leu	Tyr	Glu	Ala	Arg 240	
Asn Arg	Thr	Leu	Asn 245	Leu	Ala	Lys	Leu	Thr 250	Gly	CÀa	Ser	Arg	Glu 255	Asn	

Leu Leu Ram Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val 275	Glu	Thr	Glu	Ile 260	Ile	Lys	CÀa	Leu	Arg 265	Asn	Lys	Asp	Pro	Gln 270	Glu	Ile		
190	Leu	Leu		Glu	Ala	Phe	Val		Pro	Tyr	Gly	Thr		Leu	Gly	Val		
315	Asn		Gly	Pro	Thr	Val	_	Gly	Asp	Phe	Leu		Asp	Met	Pro	Asp		
Phe Ser Lys App Ann Asn Ser 11		Leu	Leu	Glu	Leu		Gln	Phe	ГÀа	Lys		Gln	Ile	Leu	Val	-		
340 345 346 347 348 348 349 349 349 349 340 348 349 340 348 349 340 340 348 349 340 340 340 340 340 340 340 340 340 340	Val	Asn	Lys	Asp		Gly	Thr	Trp	Phe		Val	Tyr	Gly	Ala		Gly		
1955 360 365 365 366 365 370 3870 370 370 375 37	Phe	Ser	Lys		Asn	Asn	Ser	Ile		Thr	Arg	Lys	Glu		Gln	Glu		
370 375 380 Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 385 Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 410 Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 420 Trp Met Gly Val Met His Gly Tyr Asp Ile Glu Phe Val Phe Gly Leu 425 Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 450 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 485 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 485 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 510 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 525 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 See Lys Leu Glu Met Thr Gly Asn Tyr Met Met Asp Trp Lys Asn Gln 555 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 555 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 570 210> SEQ ID NO 27 211> LENGTH: 1125 2223- OTHER INFORMATION: 12-4 mutant (Al99S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid residues 68-442 400> SEQUENCE: 27 aacatagatc aaagttttca aggettccat ggattccag cactaaacc aaaaaatgcc 120 ctcagtgaag actgtttata tctaaatgta tggattccag cactaaacc aaaaaatgcc 120	Gly	Leu		Ile	Phe	Phe	Pro		Val	Ser	Glu	Phe		Lys	Glu	Ser		
390 395 400 Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 415 Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 420 Trp Met Gly Val Met His Gly Tyr Asp Ile Glu Phe Val Phe Gly Leu 435 Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 460 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 485 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 485 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 485 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 510 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 525 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 555 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 560 **Set Ile Val Leu Chr Ser Lys Lys Glu Ser Cys Val Gly Leu 570 **Set Lys Leu Arg Ala Gln Cln Cys Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 550 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 570 **Set Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 570 **Set Trp Lys Leu Chr Trp Charter: **C210> SEQ ID NO 27 **C211> LEMOTH: 1125 **C212> TYPE: DNA **C213> ORGANISM: Artificial **C203> FEATURE: **C223> OTHER INFORMATION: 12-4 mutant (Al99S/F227A/S287G/A328W/E441D) **BCNE Turcleic acid sequence for amino acid residues 68-442 **C400> SEQUENCE: 27 **acatagatc aaagttttcc aggettccat ggatcagaga tgtggaaccc aaacactgac 60 **Ctcagtgaag actgttttat tctaaatgta tggatccag cacctaaacc aaaaaatgcc 120	Ile		Phe	His	Tyr	Thr		Trp	Val	Asp	Asp		Arg	Pro	Glu	Asn		
## Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 420 Trp Met Gly Val Met His Gly Tyr Asp Ile Glu Phe Val Phe Gly Leu 445 Pro Leu Glu Arg Arg Asp Asp Tyr Thr Lys Ala Glu Glu Ile Leu Ser 445 Arg Ser Ile Val Lys Arg Trp Ala Asp Phe Ala Lys Tyr Gly Asp Pro 480 Ass Glu Thr Gln Asp Asp Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 485 Glu Gln Lys Tyr Leu Thr Leu Asp Thr Glu Ser Thr Arg Ile Met Thr 500 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 Lys Leu Glu Met Thr Gly Asp Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asp Asp Tyr Met Met Asp Trp Lys Asp Gln 565 Phe Asp Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 570		Arg	Glu	Ala	Leu		Asp	Val	Val	Gly		Tyr	Asn	Phe	Ile			
Trp Met Gly Val Met His Gly Tyr Asp Ile Glu Phe Val Phe Gly Leu 435 Pro Leu Glu Arg Arg Asp Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 450 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 465 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 465 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 485 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 C210> SEQ ID NO 27 <211> LENGTH: 1125 <212> TYPE: DNA 213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (Al99S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 27 aacatagatc aaagttttcc aggettccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120	Pro	Ala	Leu	Glu		Thr	Lys	Lys	Phe		Glu	Trp	Gly	Asn		Ala		
Pro Leu Glu Arg Arg Asp Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 450 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 465 Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 465 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 485 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 560 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 570 C210> SEQ ID NO 27 C211> LENGTH: 1125 C212> TYPE: DNA C213> ORGANISM: Artificial C20> FEATURE: C223> OTHER INFORMATION: 12-4 mutant (Al99S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid residues 68-442 C400> SEQUENCE: 27 aacactagatc aaagttttca aggettccat ggatcagaga tgtgggaaccc aacacatgac 60 ctcagtgaag actgtttata tctaaatgta tggatccag cacctaaacc aaaaaatgcc 120	Phe	Phe	Tyr		Phe	Glu	His	Arg		Ser	Lys	Leu	Pro		Pro	Glu		
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 480 Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 495 Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565	Trp	Met	_	Val	Met	His	Gly	-	Asp	Ile	Glu	Phe		Phe	Gly	Leu		
465	Pro		Glu	Arg	Arg	Asp		Tyr	Thr	ГÀа	Ala		Glu	Ile	Leu	Ser		
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 500 Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 S20 Phe Trp Thr Ser Phe Phe Pro Lys 525 S25 Phe Pro Lys 530 Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 S50 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu S65 S60 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu S65 S20 FATURE: <pre> </pre> <210 > SEQ ID NO 27		Ser	Ile	Val	Lys		Trp	Ala	Asn	Phe		Lys	Tyr	Gly	Asn			
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 515 Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 C210> SEQ ID NO 27 C211> LENGTH: 1125 C212> TYPE: DNA C223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid residues 68-442 C400> SEQUENCE: 27 aacatagate aaagttttee aggetteeat ggateagaga tgtggaacce aaacaetgae 60 cteagtgaag actgtttata tetaaatgta tggatteeag cacetaaace aaaaaatgee 120	Asn	Glu	Thr	Gln		Asn	Ser	Thr	Ser		Pro	Val	Phe	Lys		Thr		
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 530 Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570 SEQ ID NO 27 <211> LENGTH: 1125 <212> TYPE: DNA 223> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChe nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 27 aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120	Glu	Gln	Lys		Leu	Thr	Leu	Asn		Glu	Ser	Thr	Arg		Met	Thr		
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 545 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 SEQ ID NO 27 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D) BChE nucleic acid sequence for amino acid residues 68-442 <400> SEQUENCE: 27 aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120	Lys	Leu		Ala	Gln	Gln	Cys	_	Phe	Trp	Thr	Ser		Phe	Pro	Lys		
545 550 555 560 Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 565 570 <pre> <210> SEQ ID NO 27 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)</pre>	Val		Glu	Met	Thr	Gly		Ile	Asp	Glu	Ala		Trp	Glu	Trp	Lys		
<pre> <210> SEQ ID NO 27 <211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)</pre>		Gly	Phe	His	Arg	_	Asn	Asn	Tyr	Met		Asp	Trp	Lys	Asn			
<pre><211> LENGTH: 1125 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D)</pre>	Phe	Asn	Asp	Tyr		Ser	Lys	Lys	Glu		Cys	Val	Gly	Leu				
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120	<213 <213 <213 <220 <223	1> LE 2> TY 3> OF 0> FE 3> OT BO	NGTH PE: CGANI ATUF HER ChE:	H: 11 DNA SM: RE: INFO	Art: Art: ORMA: ∋ic a	ION:	12-											
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120			-			cc ac	qqcti	ccat	. qaa	atcad	gaga	tata	qqaaq	ccc a	aaca	actgac	60	
		_		_							_		-			-		
			_	_				_		_	_					_		
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240	tat	gatgg	gca a	agtti	ctg	gc to	cgggt	tgaa	a aga	agtta	attg	tagt	gtca	aat g	gaact	atagg	240	

-continued

-continued	
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt	300
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga	360
aatootaaaa gtgtaactot otttggagaa agttooggag cagottoagt tagootgoat	420
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct	480
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct	540
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa	600
gatececaag aaattettet gaatgaagea titigtigtee eetatgggae teetitigggt	660
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt	720
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca	780
tggtttttag tetatggtge teetggette agcaaagata acaatagtat cataactaga	840
aaagaattto aggaaggttt aaaaatattt tttocaggag tgagtgagtt tggaaaggaa	900
tecateettt tteattaeae agaetgggta gatgateaga gaeetgaaaa etaeegtgag	960
geettgggtg atgttgttgg ggattataat tteatatgee etgeettgga gtteaceaag	1020
aagtteteag aatggggaaa taatgeettt ttetaetatt ttgaacaeeg ateeteeaaa	1080
cttccgtggc cagaatggat gggagtgatg catggctatg acatt	1125
<211> LENGTH: 375 <212> TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E441D BChE amino acid sequence for residues 68-442))
<400> SEQUENCE: 28	
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 1 5 10 15	
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile	
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly	
35 40 45	
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 50 60	
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 65 70 75 80	
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 85 90 95	
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 100 105 110	
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe	
115 120 125	
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 130 135 140	
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala	
145 150 155 160	
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 165 170 175	
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 180 185 190	

Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 195 200 205

Glu Ala Phe Val Val 210	Pro Tyr 215		Thr	Pro L	eu Gly 220	Val	Asn	Phe	Gly	
Pro Thr Val Asp Gly 225	Asp Phe	Leu	Thr .		et Pro 35	Asp	Ile	Leu	Leu 240	
Glu Leu Gly Gln Phe 245	Lys Lys	Thr		Ile Le 250	eu Val	Gly	Val	Asn 255	Lys	
Asp Glu Gly Thr Trp 260	Phe Leu		Tyr (Gly A	la Pro	Gly	Phe 270	Ser	Lys	
Asp Asn Asn Ser Ile 275	Ile Thr	Arg 280	Lys (Glu Pl	he Gln	Glu 285	Gly	Leu	Lys	
Ile Phe Phe Pro Gly 290	Val Ser 295		Phe (Gly L	ys Glu 300	Ser	Ile	Leu	Phe	
His Tyr Thr Asp Trp 305	Val Asp 310	Asp	Gln .	_	ro Glu 15	Asn	Tyr	Arg	Glu 320	
Ala Leu Gly Asp Val 325	Val Gly	Asp		Asn Pl 330	he Ile	CAa	Pro	Ala 335	Leu	
Glu Phe Thr Lys Lys 340	Phe Ser		Trp (Gly A	sn Asn	Ala	Phe 350	Phe	Tyr	
Tyr Phe Glu His Arg 355	Ser Ser	J60 Lys	Leu :	Pro T	rp Pro	Glu 365	Trp	Met	Gly	
Val Met His Gly Tyr 370	Asp Ile 375									
<210> SEQ ID NO 29 <211> LENGTH: 975 <212> TYPE: DNA	lficial									
<213> ORGANISM: Art: <220> FEATURE: <223> OTHER INFORMA:	TION: 12									
<220> FEATURE: <223> OTHER INFORMATED BChE nucleic	FION: 12 acid seq	uence	for	amin	o acid	resi	.dues	s 117	7-441	60
<pre><220> FEATURE: <223> OTHER INFORMA!</pre>	FION: 12 acid seq tc atctt	uence tacat	for	amino	o acid	resi agttt	due:	3 117	gggtt	60
<pre><220> FEATURE: <223> OTHER INFORMA!</pre>	TION: 12 acid seq tc atctt tc aatga	uence tacat actat	gtt	amino tatga gtggg	o acid	resi agttt	dues	ggete	gggtt	
<pre><220> FEATURE: <223> OTHER INFORMA:</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga	uence tacat actat acatg	for gtt agg	amino tatga gtggg ttatt	o acid tg gcaa tg ccct tg atca	resi agttt agga aacag	dues	ggete ggete ettag	egggtt ectttg	120
<pre><220> FEATURE: <223> OTHER INFORMA!</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct	uence tacat actat acatg ttggt	for gtt agg	amino tatga gtggg ttatt aatcc	tg gcaa tg ccct tg atca ta aaag	resi agttt agga aacag gtgt <i>a</i>	dues	ggete ettag ggete	gggtt gggtt getttg ettcag	120 180
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	FION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta	uence tacat actat acatg ttggt	gtt agg ggt ggt	amino tatga gtggg ttatt aatcc ttgct	tg gcaattg ecct tg atca ta aaaq tt etce	resi agttt agga aacac gtgta	dues	ggete ettag ggete eetet	egggtt getttg ettcag ettgga	120 180 240
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg	uence tacat actat acatg ttggt gcctg gttcc	gtt aggr ggt gga cat	amino tatga gtggg ttatt aatcc ttgct aatgc	tg gcaatg gcccttg atca ta aaaqtt ctcc	resi agttt agga aacag gtgta ctgga	dues	ggete ettag ggete eetet eetet	egggtt getttg ettcag ttgga cattg	120 180 240 300
<pre><220> FEATURE: <223> OTHER INFORMAT BCHE nucleic a <400> SEQUENCE: 29 ggttttcaaa ctggaacat gaaagagtta ttgtagtgt ccaggaaatc ctgaggcta tgggttcaaa aaaatataa gaaagttccg gagcagcta ttcaccagag ccattctga</pre>	FION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga	uence tacat actat acatg ttggt gcctg gttcc actta	gtt: agg ggt ggt gga gga ggt	amino tatgar gtgggr ttattr aatccr ttgctr aatgcr aatgcr	tg gcaa tg ccct tg atca ta aaaq tt ctcc tc cttq	resi agttt agga aacac gtgta ctgga gggcc gttgc	dues	ggete ettag ggete eetet eeatt aacat	egggtt getttg ettcag ettgga ecattg ectctt	120 180 240 300 360
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta	uence tacat actat acatg ttggt gcctg gttcc actta gaaat	gtt agg ggt ggt ggt ggt. ggt. gct. aaa	amino tatgat gtgggt ttatt aatcct ttgct aatgct aaatgc	tg gcad tg ccct tg atca ta aaag tt ctcc tc cttc ga ctgg cc aaga	resi agttt agga aaacag gttga gggggcg gttga	dues	117 gggete tettag ggete cetet ecatt ceatt	gggtt gctttg ettcag ettgga cattg ectct gagaat	120 180 240 300 360 420
<pre><220> FEATURE: <223> OTHER INFORMA:</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta gg gactc	tacat actat acatg ttggt gcctg gttcc actta gaaat ctttg	gtt agg ggt gga cat gct aaaa ggt	amino tatgat ttatt aatcct aatgct aatgct aatgct gatcco	tg gcaa tg ccct tg atca ta aaaa tt ctcc tc ctta ga ctga cc aaga	resi agttt aggs aacag gtgts ctggs ggggg g gttgc	dues	s 117 s 117	gggtt gctttg ettcag ettga ccattg cctctt gagaat atgaa	120 180 240 300 360 420 480
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq to atott to aatga co aggga go agoet to agtta ca aagtg ac gttga tg tetta tg gacte	uence tacat actat actat gcctg gcctg gttcc actta gaaat ctttg tatta	gtt aggt gga cat gct. aaaa ggt.	amino tatgal gtgggl ttatte aatcel aatgel aaatte gatee ggtaaae	tg gcad tg ccct tg atco ta aaaa tt ctcc tg ctg cc aaga ct ttg tg gacd	resi agttt tagga aaacag gtgta ttgga ggggcg gttgc	dues	117 117 117 117 117 117 117 117	gggtt ggtttg ettcag ettgga cattg etctt ggaat atgaa gatggt	120 180 240 300 360 420 480 540
<pre><220> FEATURE: <223> OTHER INFORMA:</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta gg gactc cc agaca aa agatg	uence tacat actat acatg ttggt gcctg gttcc actta gaaat ctttg tatta aaggg	gtt agg ggt gga cat gct aaaa gct actt aca	amino tatgat gtgggg ttatte aatce ttgcte aaatte gatce gtaaae gaacte tggtte	tg gcaa tg ccct tg atca ta aaaq tt ctcc tc cttq ga ctgg cc aaga ct ttgg tg gaca	resi aggttt aggs aacag gtgts ttggs gttgc gttgc aaatt	dues ct q tt q aac t aag q tc t cct t cct t aaa a	117 ttag ggete cetet	gggtt gctttg ttcag ttgga cattg cctctt ggaat atgaa gatggt	120 180 240 300 360 420 480 540
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta gg gactc cc agaca aa agatg	uence tacat actat actat gcctg gcctg gttcc actta ctttg tatta aaggg	gtt agg ggt ggt gga cat gct. aaa aga aga	amino tatgat gtgggg ttatt aatcc aatgct aaatt gatcc gtaaac gtaaac ttggtt aaagaa	tg gcaatg cccttg atccctc cttg ccc agactt ttggttt tagtat ttcagtat t	resi aggttt agggaaacag gtgta etgga gggggg gttgc gggggaaattt cctat	dues cct q tt q gtt q aggt a cct t cct t cct t ggg t ggg t	117 gggctc cctct ccatt ccatt ccatt cctga cctga cctga	gggtt ggtt gtttag ettcag ettga cattg etctt agaat atgaa atggt eccag ectggc	120 180 240 300 360 420 480 540 600
<pre><220> FEATURE: <223> OTHER INFORMA!</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta gg gactc cc agaca aa agatg ag tatca	uence tacat actat actat acatg ttggt gcctg gttcc actta gaaat tatta aaggg ttacta gaaag	gtt agg ggt gga cat gct aaaa ggt ctt agg gga agg gga agg gga gga gga gga g	amino tatgat gtgggf ttatt aatcct aatgct aaatt ggtccc ggtaaac ggactt tggtt aaagaa tccatc	tg gcaatg coot tg atcatt ctcc ctt; ga ctg; cc aagg; tg gacatt tagt at tagt at ttcatcc ct ttcatcc cc tttatcc	resi aggttt tagga aacag gtgta ttgga ggggcg gttgc aaatt tcctat	dues ct q gtt q aac t aag q ct t caa a aaa a aag gt t caa a aaa a aag gt t caa a aaa a	tttaa gggctc cctct ccatt ccatt ccatt cctga cctga cctga cctga cctga cctga	gggtt ggtttg ettcag ettga cattg ctctt gagaat aatgaa gatggt eccag ectggc aaaata gactgg	120 180 240 300 360 420 480 540 660 720
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta gg gactc cc agaca aa agatg ag tatca ga gtttg	uence tacat actat actat gcctg gttcc actta gaaat tatta aaaggg taact gaaac	gtt aggregation ggt ggt ggt ggt ggt aaa ggt aggregation ggt acat ggt acat ggt acat ggt ggt acat ggt ggt ggt ggt ggt ggt ggt ggt ggt g	amino tatgat gtgggg ttatt aatcc ttgct aaatc gatcc ggtaaac ggact tggtt aaaga tccat gcctt gcctt	tg gcaatg cool tg atcatt ctcc cttg ga ctgg ct ttgg tt tagg at ttcagg gtgg gt	resi agttt aggttt aggttt gga aacag ggggg gttgc aaattt cctat cctat atgtt	dues cct c gtt c ggt a agg t cct t ggg t cct t ggg t ggg t cct t cct t ggg t cct t cct t ggg t cct	ggetcetttag cetet ceatt ceatt ceatt cagage cetga aaaaa cegetce tttaa	gggtt ggtt gtttag ettcag ettga ecattg ectctt gagaat gatgat gctggc gatatat	120 180 240 300 420 480 540 660 720
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta cg gactc cc agaca aa agatg ag tatca ga gtttg ga aaact tt ggagt	uence tacat actat actat acatg ttggt gcctg gttcc actta gaaat tatta aaggg taact taact gaaacg ttacc ttacc	gtt agg ggt gga cat gct aaaa aga aga gag aaag	amino tatgat gtgggg ttatt aatcct aatgct aaattc gatccc gtaaac ttggtt aaagat tccatc	tg gcaatg coot tg atcate tt ctcc cttg ga ctgg ct ttgg gacatt ttgg gacatt ttgg gacatt ttgg gacatt ttgg gacatt tagg gacatt ttgg cc cagg	resi aggttt cagga aacag gtgta ggggcg ggggcg gttgc aaatt cctat acggaa ttcat	dues cct q gtt q ac t aag q ggt a aa a aa a aag q ggt t aa a aa a ag qgt a ag qgt a	117 THE STATE STA	gggtt ggtttg ttcag tttga cattg ctttt gagaat aatgaa gatggt cccag cctggc aaata actgg	120 180 240 300 360 420 540 600 720 780 840
<pre><220> FEATURE: <223> OTHER INFORMAT</pre>	TION: 12 acid seq tc atctt tc aatga cc aggga gc agcct tc agtta ca aagtg ac gttga tg tctta cg gactc cc agaca aa agatg ag tatca ga gtttg ga aaact tt ggagt	uence tacat actat actat acatg ttggt gcctg gttcc actta gaaat tatta aaggg taact taact gaaacg ttacc ttacc	gtt agg ggt gga cat gct aaaa aga aga gag aaag	amino tatgat gtgggg ttatt aatcct aatgct aaattc gatccc gtaaac ttggtt aaagat tccatc	tg gcaatg coot tg atcate tt ctcc cttg ga ctgg ct ttgg gacatt ttgg gacatt ttgg gacatt ttgg gacatt ttgg gacatt tagg gacatt ttgg cc cagg	resi aggttt cagga aacag gtgta ggggcg ggggcg gttgc aaatt cctat acggaa ttcat	dues cct q gtt q ac t aag q ggt a aa a aa a aag q ggt t aa a aa a ag qgt a ag qgt a	117 THE STATE STA	gggtt ggtttg ttcag tttga cattg ctttt gagaat aatgaa gatggt cccag cctggc aaata actgg	120 180 240 300 360 420 600 660 720 780 840

<210> SEQ ID NO 30 <211> LENGTH: 325		
<212> TYPE: PRT <213> ORGANISM: Artificial		
<pre><220> FEATURE: <223> OTHER INFORMATION: 12-4 mutant (A199S/F227A/S287G/A328W/E</pre>	(4.1.D)	
BChE amino acid sequence for residues 117-441		
<400> SEQUENCE: 30		
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 1 5 10 15	•	
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 20 25 30	-	
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 35 40 45	7	
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 50 55 60	;	
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 65 70 75 80	7	
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 85 90 95	,	
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 100 105 110	ı	
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 115 120 125	ı	
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 130 135 140	:	
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 145		
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro 165 170 175)	
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 180 185 190	ı	
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 195 200 205)	
Glu Gly Thr Trp Phe Leu Val Tyr Gly Ala Pro Gly Phe Ser Lys Asp 210 215 220)	
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 225 230 235 240		
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 245 250 255	;	
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 260 265 270	ı	
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 275 280 285	ı	
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 290 295 300	:	
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 305 310 315 320		
Met His Gly Tyr Asp 325		

What is claimed is:

- 1. A butyrylcholinesterase variant peptide comprising the amino acid sequence of SEQ ID NO: 20.
 - 2. A pharmaceutical composition comprising:
 - a butyrylcholinesterase variant peptide comprising the 5 amino acid sequence of SEQ ID NO: 20 and a suitable pharmaceutical carrier.
- 3. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of

98

the butyrylcholinesterase variant polypeptide of claim ${\bf 1}$ to lowering blood cocaine concentration.

4. The method of claim **3**, wherein said butyrylcholinesterase variant polypeptide exhibits a one-hundred-fold or more increase in cocaine hydrolysis catalytic efficiency compared to wild-type butyrylcholinesterase.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,438,904 B1 Page 1 of 1

APPLICATION NO.: 11/243111
DATED: October 21, 2008

INVENTOR(S) : Zhan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 1, line 12, insert the following:

-- Government Support

Research for this invention was made with support from the National Institute of Health/NIDA, Grant Number R01DA013930. The United States Government has certain rights to this invention. --

Signed and Sealed this

Eighteenth Day of May, 2010

David J. Kappos

Director of the United States Patent and Trademark Office

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,438,904 B1 Page 1 of 1

APPLICATION NO. : 11/243111
DATED : October 21, 2008
INVENTOR(S) : Zhan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 97, line 1-2, should read,

1. A butyrylcholinesterase variant peptide comprising an amino acid sequence of SEQ ID NO 20.

Column 97, lines 8-9 - Column 98, lines 1-2 should read,

- 3. A pharmaceutical composition comprising:
- a butyrylcholinesterase variant peptide comprising the amino acid sequence of SEQ ID NO 20 and a suitable pharmaceutical carrier.

Column 98, lines 3-6 should read,

4. A method of treating a cocaine-induced condition comprising administering to an individual an effective amount of the butyrylcholinesterase variant polypeptide of claim 1 to lowering blood cocaine concentration.

Column 98, lines 7-8 should read,

5. The method of claim 4, wherein said butyrylcholinesterase variant polypeptide exhibits a one-hundred-fold or more increase in cocaine hydrolysis catalytic efficiency compared to wild-type butyrylcholinesterase.

Signed and Sealed this First Day of February, 2011

David J. Kappos

Director of the United States Patent and Trademark Office